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Despite the advancements in therapies, next-generation sequencing, and our 
knowledge, breast cancer is claiming hundreds of thousands of lives around the world 
every year. We have therapy options that work for only a fraction of the population due 
to the heterogeneity of the disease. It is still overwhelmingly challenging to match a 
patient with the appropriate available therapy for the optimal outcome. This dissertation 
work focuses on using biomedical informatics approaches to development of pathway-
based biomarkers to predict personalized drug response in breast cancer and assessment 
of feasibility integrating such biomarkers in current electronic health records to better 
implement genomics-based personalized medicine.  
The uncontrolled proliferation in breast cancer is frequently driven by 
HER2/PI3K/AKT/mTOR pathway. In this pathway, the AKT node plays an important 
role in controlling the signal transduction. In normal breast cells, the proliferation of cells 
is tightly maintained at a stable rate via AKT. However, in cancer, the balance is 
disrupted by amplification of the upstream growth factor receptors (GFR) such as HER2, 
IGF1R and/or deleterious mutations in PTEN, PI3KCA. Overexpression of AKT leads to 
increased proliferation and decreased apoptosis and autophagy, leading to cancer. Often 
these known amplifications and the mutation status associated with the disease 
progression are used as biomarkers for determining targeting therapies. However, 
downstream known or unknown mutations and activations in the pathways, crosstalk 
iv 
between the pathways, can make the targeted therapies ineffective. For example, one 
third of HER2 amplified breast cancer patients do not respond to HER2-targeting 
therapies such as trastuzumab, possibly due to downstream PTEN loss of mutation or 
PIK3CA mutations. To identify pathway aberration with better sensitivity and specificity, 
I first developed gene-expression-based pathway biomarkers that can identify the 
deregulation status of the pathway activation status in the sample of interest. Second, I 
developed drug response prediction models primarily based on the pathway activity, 
breast cancer subtype, proteomics and mutation data. Third, I assessed the feasibility of 
including gene expression data or transcriptomics data in current electronic health record 
so that we can implement such biomarkers in routine clinical care.   
To my parents Arifur Rahman, and Roushan Akter 
And my mother-in-law, Rokeya Islam. 
“A question that sometimes drives me hazy: am I or are the others are crazy?”-Albert 
Einstein 
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Breast cancer is a heterogeneous disease claiming approximately 450,000 lives every 
year worldwide (1). In 2014, 41,000 women died of the disease, accounting for 15% of 
cancer-related deaths in the United States. Traditionally, clinical-pathological markers are 
used for breast cancer treatments based on the size, grade, lymph node involvement, or 
metastasis status, known as the tumor, node, and metastasis (TNM) grading system (2). 
Additionally, three receptor-based biomarkers— estrogen, progesterone, and HER2 
receptor status have been used for clinical treatment decision-making. Hormone receptor 
positive patients receive estrogen modulator therapies, and HER2-amplified patients 
receive HER2-targeted therapies in addition to chemotherapy. Many patients relapse or 
do not respond to targeted therapies even with the presence of these 
immunohistochemically measurable biomarkers. More recently, with the advent of next-
generation sequencing technology, molecular profiling of tumors has identified complex 
genomic abnormalities or subtypes of cancer that can be of significant value to breast 
cancer management (3). These findings show the heterogeneity of breast cancer demands 
more careful determination of aberrant signaling in selecting personalized cancer therapy 
for better treatment outcome. Growth factor receptor pathways are recognized as one of 





cell proliferation and cell death. However, in cancer cells, this homeostasis is disrupted, 
and cells continue to proliferate uncontrollably, resisting cell death (4).   
 
1.1 Overview 
 AKT, also known as protein kinase B (PKB), is a protein that is critical for growth 
factor receptor signaling cascades important in various diseases such as cancer, type 2 
diabetes, and Alzheimer’s disease. AKT is frequently deregulated in many cancers via 
upstream growth factor receptors, activating mutations in PI3KCA and loss of function 
mutations in PTEN. Activated AKT increases cell proliferation, survival, transcription, 
tumor suppression, tissue invasion and chemo-resistance (5, 6). Therefore, AKT has been 
an appealing target in multiple cancer treatments. However, AKT inhibitors show 
therapeutic benefits only in a subset of patients, and it is often challenging to leverage the 
underlying genomic features that make someone sensitive to AKT inhibitors to predict 
therapy response (7, 8). Clinical trial results show that knowing the mutation status 
leading to activation of the target is insufficient to predict drug response (9). Failure to 
predict drug response is possibly due to the interaction between target and downstream 
deregulations and alternative pathways. Therefore, better approaches are needed to model 
AKT activity so that we can match patients with the right therapy. Gene expression 
signatures, sets of gene expression levels representing a biological phenomenon such as 
pathway activation, have been shown to be efficacious in predicting drug response. 
Previous studies showed that genomic analysis could identify pathway activation, which 
is important to tumor growth and response to therapy (10-13). Our approach to 





aberration. If an aberrant AKT signaling genomic pattern or AKT signature could be 
identified, it would be possible to apply that signature to patients’ tumors to measure the 
level of AKT activation independent of the activation method. Because of the inherent 
interconnectedness or the crosstalk among pathways, it is fundamentally challenging to 
identify a particular genomic signature for a targeted therapy. My first goal in this 
dissertation is to identify the AKT signature accounting for crosstalks in growth factor 
receptor networks and to build a predictive model for AKT inhibitors’ 
sensitivity/resistance in an individual. 
   In addition, the complexity and the volume of gene expression data make it unrealistic 
for clinicians to use such data in routine clinical cases without any decision aids. 
Clinicians have little to no training in the usage of gene expression data. However, 
currently available standard information models used by electronic health record (EHR) 
systems fall short in representing, storing, and exchanging gene expression data so that 
data can be computable and usable for active clinical decision support (CDS) (14). 
Despite the proven benefits of using gene expression-based biomarkers, to date it is not 
feasible to integrate gene expression data in the EHR for routine clinical care. Therefore, 
my second goal here is to leverage and adapt currently available international standards 
and terminologies to design an information model for representing gene expression data.  
The promises of personalized medicine remain elusive to date due to challenges in 
matching specific genomic aberration in an individual to their drug response. Therefore, 
the goal of this dissertation is to take data produced at the bench, apply it to control 
dataset to identify biomarkers, and finally to study the feasibility of implementation of 





biomarkers can be used in patient care decision-making. Specifically, development of 
pathway and drug response biomarkers falls in the translational biomedical informatics 
domain and assessment of feasibility of integrating gene expression data falls in the 
clinical informatics domain. Below is the specific significance of my work for this 
dissertation.  
 
1.2 Effects of AKT deregulation in cancer 
As noted above, the AKT signaling pathway, also known as the protein kinase B 
(PKB) pathway, has a major role in the development and progression of cancer. First, 
activated AKT promotes cell proliferation by inhibiting cell cycle inhibitors such as 
forkhead box proteins O 1, 3, 4 (FOXO1/3/4). Second, AKT activates protein synthesis 
and cell growth via mTOR, which ultimately leads to increased proliferation and loss of 
cell cycle control. AKT also regulates autophagy, autophagosomic lysosomal degradation 
of bulk cytoplasmic contents, via mTOR. Third, AKT can inhibit apoptosis by binding to 
pro-apoptotic proteins such as BAD and BAX. AKT can be activated by upstream growth 
factor receptors (GFR) such as HER2, IGF1R and G-protein coupled (GPC) receptors via 
phosphoinositde 3-kinase (PI3K) signaling. In addition, estrogen can activate the 
PI3K/AKT pathway in an estrogen receptor (ER) independent manner (15). Activated 
AKT has been shown to interfere with tamoxifen-induced apoptosis (16).  
 
1.3 Significance of targeting AKT deregulation 
Single gene-based biomarkers have shown promise as a biomarker in some cases. 





with HER2-targeted therapy such as trastuzumab (17). However, one third of the patients 
exhibiting amplification of HER2 do not respond to this drug, probably because of 
deregulation of downstream or parallel pathways such as PTEN or PI3K (18-21).  Sangai 
et al. (2012) described loss of function of PTEN and activating PIK3CA mutations as a 
clinical biomarker for MK2206, a small molecular inhibitor of AKT1 and AKT2 (22). 
Sommer et al. (2013) identified elevated serum and glucocorticoid regulated kinase 
(SGK1) to be predictive of resistance to AKT inhibitors in breast cancer (23). However, 
these studies do not address the fact that alternative pathways, for example, by HER2, 
IGF1R or RAS, can activate AKT. Thus, one or two gene-based biomarkers fail to 
predict drug response with high sensitivity and specificity. These findings demand further 
exploration of the effects of interactions among growth factor receptor pathway 
activation, mutation status and crosstalk in different networks to predict drug sensitivity 
in cancer patients. Previous efforts have shown that the multigene-based gene expression 
profile, a signature, is predictive of therapy responses by correctly identifying target 
deregulation (10-13). The approach here is to identify a representative multigene 
expression pattern of AKT deregulation, an AKT signature, to predict AKT pathway 
deregulation considering crosstalk. One of the ultimate goals of this proposal is to 
generate, validate and test drug-specific response prediction models targeting AKT 









1.4 Significance of gene expression data integration with the Electronic  
Health Record 
Since the advent of high-throughput genomic profiling technologies such as gene 
expression microarrays and RNA-Seq, biomarkers such as OncotypeDX and 
Mammaprint have been developed for guiding clinicians with disease diagnosis, 
prognosis and treatment decisions (10, 24-28). Nevertheless, there remains a significant 
gap between the scientific knowledge and routine use of gene expression data in clinical 
practice. The National Human Genome Research Institute initiated the Electronic 
Medical Records and Genomics (eMERGE) (29, 30) consortium to bridge this gap by 
developing interoperable systems that can integrate genomic data with the clinical 
workflow (Integrating Large-Scale Genomic Information into Clinical Practice, 2012). 
However, the eMERGE consortium so far has focused mainly on integrating gene 
variants and genetic testing reports in the EHR. In a recent publication, it was recognized 
that the “mechanism for long-term storage of genomic data as well as secure, 
generalizable, and interoperable data exchange between healthcare settings are needed to 
ensure continuity of care” (14). 
 
1.5 Challenges to integrating gene expression data with  
Electronic Health Record (EHR)  
Gene expression data offer many opportunities to improve clinical care, but many 
significant barriers hinder the effective use of such data. These barriers include an 
inadequate standardized laboratory reporting method; the complexity of the analysis; the 





understanding of actionable clinical value, and insurance reimbursement for genomics 
testing; information overload; and continual updating of genomic knowledge. Due to 
these significant barriers, very little to no progress has been made to integrate gene 
expression data into the EHR. Biomarkers such as OncotypeDX and Mammaprint are 
outsourced to specialized companies as genomic tests. The companies performing gene-
expression-based tests send actionable scores back to the clinicians after performing the 
test. The scores frequently are not included into the EHR in computable format. Gene 
expression data used in clinical trials are stored outside the EHR in various formats. 
Therefore, significant work needs to be done to accommodate the integration of actual 
gene expression data from these clinical biomarker tests so that data computation and 
sharing of the data are feasible. 
Effective genomics data sharing and integration to the EHR is  key for the adoption of 
genomics information in routine clinical care. In addition, genomics data need to be 
represented in computable format and, hence, can be used in clinical decision support 
(CDS) for guiding clinicians, improving quality of care and reducing adverse drug events 
(31-35). CDS is recognized as necessary to help reduce information overload for 
clinicians and to facilitate appropriate up-to-date use of genomic information (36-38). To 
address data sharing and integration between clinical research data and the EHR, 
researchers have proposed detailed clinical modeling (DCM), a basis for retaining 
computable meaning when data are exchanged between heterogeneous computer systems 
across a variety of concepts, has been used (39). Among various international efforts, the 
openEHR Foundation has published a health information reference model, which consists 





the Clinical Information Modeling Initiative (CIMI), an international consortium, is 
dedicated to providing a common format for representation of health information content 
so that semantic interoperability can be assured through evolving standards for 
representing clinical information. If gene expression data were to present in the EHR 
using the reference model constraints, gene expression data could be (1) represented as 
both human readable for human cognition and machine readable for CDS 
implementation; (2) shared with different systems, retaining semantic and computable 
meaning; (3) updated regularly and more efficiently based on current knowledge; and (4) 
stored, accessed and used in a cost-effective way. In this dissertation, I have explored the 
feasibility of representing gene expression data with open standard health information 
modeling efforts. In cases where standards, terminology, or data models were 
unavailable, I proposed a preliminary data model integrating best practices. 
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Abstract
Motivation: Although gene-expression signature-based biomarkers are often developed for clinical
diagnosis, many promising signatures fail to replicate during validation. One major challenge is
that biological samples used to generate and validate the signature are often from heterogeneous
biological contexts—controlled or in vitro samples may be used to generate the signature, but pa-
tient samples may be used for validation. In addition, systematic technical biases from multiple
genome-profiling platforms often mask true biological variation. Addressing such challenges will
enable us to better elucidate disease mechanisms and provide improved guidance for personalized
therapeutics.
Results: Here, we present a pathway profiling toolkit, Adaptive Signature Selection and
InteGratioN (ASSIGN), which enables robust and context-specific pathway analyses by efficiently
capturing pathway activity in heterogeneous sets of samples and across profiling technologies.
The ASSIGN framework is based on a flexible Bayesian factor analysis approach that allows for
simultaneous profiling of multiple correlated pathways and for the adaptation of pathway signa-
tures into specific disease. We demonstrate the robustness and versatility of ASSIGN in estimating
pathway activity in simulated data, cell lines perturbed pathways and in primary tissues samples
including The Cancer Genome Atlas breast carcinoma samples and liver samples exposed to geno-
toxic carcinogens.
Availability and implementation: Software for our approach is available for download at: http://
www.bioconductor.org/packages/release/bioc/html/ASSIGN.html and https://github.com/wevan
johnson/ASSIGN.
Contact: andreab@genetics.utah.edu or wej@bu.edu
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Since the advent of high-throughput genomic profiling technologies
such as gene expression microarrays and RNA-Seq, many computa-
tional and statistical methods have been developed to derive gene
expression signatures for disease diagnosis, prognosis and treatment
decisions (Golub et al., 1999; Saeys et al., 2007; van de Vijver et al.,
2002). Gene expression signatures are often used as surrogate repre-
sentations of pathway activation or deactivation. The use of
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expression signatures to quantify pathway activation level has been
particularly important for dissecting the complexity of diseases and
providing guidelines of targeted therapeutics. To date, gene expres-
sion-based pathway analyses mainly face two sources of challenges:
(i) limited pathway annotations in curated databases and (ii) inef-
fective analysis tools.
In reference to the first limitation, many public databases
(Ashburner et al., 2000; Kanehisa et al., 2014; Liberzon et al., 2011)
provide manually curated pathways that associate genes lists with
pathway activity. However, genes in those predefined pathways are
not always associated with gene expression changes that differ
between disease states. For example, some genes in an annotated
pathway might be activated through changes in phosphorylation or
protein interaction status. Thus, pathway analysis approaches that
use patient gene expression profiles without careful selection for
expression-based signature genes with transcriptional change
may lead to incorrect results. An alternative way to infer pathway
activity is by experimentally perturbing the pathway of interest in
controlled settings and projecting the associated molecular signature
(e.g. changes in gene expression) onto patient or other target sam-
ples to estimate pathway activity levels (Bild et al., 2006; Gustafson
et al., 2010; Sweet-Cordero et al., 2005). For example, previous
efforts have generated gene expression signatures for growth factor
signaling pathways in human primary cells and then used the signa-
tures to predict disease prognosis and drug sensitivity in human can-
cer cohorts (Bild et al., 2006). Although, these pathway-profiling
approaches have been previously shown to generate empirical gene
expression-based pathway response signatures, the assumption of
homogeneity between in vitro (e.g. perturbation samples) and
in vivo (e.g. patient) biological conditions does not always hold due
to platform, tissue or disease deregulation status variations.
In effort to address the second concern, factor analysis
approaches have been used to identify latent factors (metagenes)
associated with pathways and clinical outcome (Bazot et al., 2013;
Bhattacharya and Dunson, 2011; West, 2003). However, it is often
difficult to interpret the biological meaning of the latent factors
identified by these unsupervised approaches or to estimate the abso-
lute activation level for pathways of interest. Supervised classifica-
tion approaches (Pirooznia et al., 2008) often model pathways one
at a time without accounting for pathway correlation or interaction
between related pathways. Moreover, supervised classification
approaches require expression data from pathway perturbation
experiments for building up models, thus often fail to work when
only pathway gene lists are available. So far, none of these existing
approaches adequately account for tissue, disease or context specifi-
city in assessing gene expression signatures regulated via pathway
activation or deactivation. Furthermore, none of them are designed
to profile genomic signatures across multiple genomic profiling
platforms.
To overcome these limitations, we propose a novel and flexible
pathway profiling toolkit called Adaptive Signature Selection and
InteGratioN (ASSIGN). ASSIGN relies on a sparse Bayesian factor
analysis method to estimate the activation status of pathways under
investigation, such as oncogenic pathways, immune response path-
ways or drug response pathways in individual samples of a genomic
dataset for predicting optimal treatment prior to any medication on
patients. Here, we use multiple simulated and real datasets to demon-
strate the validity and robustness of ASSIGN in estimating pathway
activation. In simulated data, the model correctly adapts the pathway
signature gene lists in specific biological contexts by excluding
irrelevant genes or including relevant genes into signatures. We used
five previously published oncogenic signaling pathway signatures to
demonstrate the advantages of modeling multiple pathways in concert
to account for crosstalk among the pathways. We also used the tumor
samples from The Cancer Genome Atlas (TCGA) to show that
ASSIGN can robustly combine in vitro signatures generated using
one profiling platform with tumor samples profiled using a different
platform. Finally, we used profiling data generated from liver tissues
exposed to genotoxic hepatocarcinogens to demonstrate the versatil-
ity of ASSIGN in identifying and adapting signatures from pre-
curated pathway gene lists. Overall, ASSIGN uses a semi-supervised
approach that results in more biologically interpretable pathway
activation profiles that are adapted to specific tissues or disease con-
texts, as opposed to more rigid and less interpretable profiles gener-
ated by previous approaches. Although, ASSIGN was initially
designed for pathway-based analysis from gene expression data,
it can easily be extended to other profiling data types such as DNA
variation or methylation data.
2 Approach
We define a ‘signature’ as a set of representative genes whose expres-
sion changes due to differences in disease status, exposure to a chem-
ical compound/drug or differential regulation of key pathway genes.
The signature can also optionally contain the absolute direction
changes or expression magnitude changes due to an experimental
perturbation. ASSIGN is a pathway analysis toolkit with the flexibil-
ity to accommodate profiling analysis needs for a large number of
pathways or perturbation profiling scenarios. ASSIGN allows the
user the option of choosing either Bayesian regression (signatures
known) or factor analysis (signatures unknown) and accommodates
multiple signatures simultaneously within a set of samples. Key
innovations in ASSIGN allow for broad applicability of the method
(Table 1), whereas other existing approaches lack one or more of
these critical features. The specific advantages of ASSIGN are
described below.
2.1 Simultaneous profiling of multiple pathways
ASSIGN can account for pathways simultaneously, compared with
other approaches that only consider a single pathway at a time
[GSEA (Subramanian et al., 2005), ssGSEA (Barbie et al., 2009),
BFRM (West, 2003)]. This feature accounts for ‘cross-talk’ between
pathway components by directly modeling correlations and inter-
actions in the pathway signature components that might reduce de-
tection sensitivity and specificity.
2.2 Context specificity in baseline gene expression
Baseline gene expression levels (i.e. expression level when a pathway
is inactive) may vary widely due to differences in tissue types or
disease status, or across different measurement platforms and can
contribute to heterogeneity between in vitro perturbation samples
and patient samples. ASSIGN can adaptively estimate background
gene expression levels across a set of samples, giving it the unique
ability to estimate absolute pathway activity levels or drug efficacy in
clinical samples before the samples have received a treatment, even
when the signature was generated using a different profiling platform.
2.3 Context specific signature estimation
Many existing signature-based profiling approaches require input
signatures in the form of a gene list [GSEA, FacPad (Ma and Zhao,
2012)] or a gene list with static expression magnitude changes
(BFRM). While BFRM provides a direct and supervised approach
for pathway profiling, it requires the signature to be generated in the
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same biological context as the patient samples. FacPad allows for
the adaptation of signature profiles, but cannot integrate magnitude
change information. In addition, FacPad is highly impacted by out-
liers in the dataset and often suffers from the lack of identifiability
of the direction of the signature magnitude. ASSIGN provides the
flexibility to use either a signature-based or gene list-based approach
and can also use input magnitudes as prior information, thus provid-
ing a compromise that allows for adaptive signature refinement
while reducing signature over-fitting and direction ambiguity.
2.4 Regularization of signature strength estimates
ASSIGN regularizes signature strength estimates using Bayesian
ridge regression (Hsaing, 1975), which ‘shrinks’ signature strength
estimates toward zero, especially for signatures with a weak
presence or anecdotal correlations in the sample. In addition, ridge
regression has well-established benefits in handling correlated
covariates (Hsiang, 1975), thus making it advantageous for the
simultaneous modeling of correlated signatures.
3 Methods
3.1 Formal definition of ASSIGN model
To define the model formally, suppose a gene expression assay pro-
files G genes on N patient samples of a certain disease type, and let
Y be a G ! N matrix of observed expression values. Each entry in Y
is a gene expression value after data normalization. We apply a
Bayesian sparse factor model to decompose the Ymatrix as:
YG!N ¼ BG!1101!N þ SG!KAK!N þ EG!N (1)
Each column of Y represents all the genes for one patient
sample. We model the measured expression values of each
patient sample in a vector form: Y$;j % NðBþ SA$;j; RÞ;
where R ¼ diagðs(11 ; . . . ; s(1G Þ for j ¼ 1; . . . ;N. Figure 1 contains a
visual representation of the ASSIGN model.
B is a G-vector of the baseline gene expression levels for all
genes. We define the prior distribution of B as B % NðlB; SBÞ. The
prior parameters lB and SB can be set as non-informative or inform-
ative from control samples in a pathway perturbation experiment.
Matrix S is the G ! K factor loading matrix, with each column
representing the gene expression signature of a specific biological
pathway. In whole-genome expression profiling, we expect that the
majority of genes will not show differential expression in associ-
ation with any particular factor, and each individual factor
will be associated with only a few genes. Thus, the columns k
of S will be sparse. The hierarchical spike-and-slab prior
distribution of S is: Sg;kjdg;k % ð1( dg;kÞNð0;x20Þ þ dg;kNð0;x21Þ;
where dg;k % Bernoulliðpg;kÞ; for g ¼ 1; . . . ;G;k ¼ 1; . . . ;K. dg;k
is a Bernoulli-distributed binary indicator for Sg;k (dg;k ¼ 0: the gene
is excluded from the signature; dg;k¼1: the gene is included in the
signature). dg;k is sampled with probability pg;k. Sg;k has a diffuse
prior (x1¼1) when dg;k¼1, and a highly precise prior (x0¼0.1)
when dg;k¼0. The choice of prior pg;k depends on the prior infor-
mation of pathway signatures (see Section 3.2 for details).
Matrix A is the K!N factor score (pathway activity) matrix,
with each column A.,j representing activation scores of the K path-
ways for each individual patient sample. Since tumors often rely on
the activation of one or two pathways, such as via an ‘oncogene ad-
diction’ (Weinstein, 2002), not all of the K pathways will necessarily
be activated in all the individual patient samples. Therefore, any col-
umn of A will likely be sparse. Thus, we model the matrix A using a
hierarchical spike-and-slab prior similar to the formulation for S.
To overcome the ‘sign-flipping’ phenomenon (e.g. non-identifiabil-
ity) that commonly occurs in factor analysis, we used a truncated
normal distribution (0, 1 range) in a modified slab normal prior:







leading to better interpretability of absolute pathway activation lev-
els. In this prior, U is the cumulative function of the standard normal
Fig. 1. Visual representation of ASSIGN model







Predefined gene list x x x x
Magnitude changes x x
Perturbation expression profiling data x x
Advanced model features
Multiple signatures x x x
Context-specific background x
Context-specific signature x x x
Pathway activity regularization x x
Method output
Biologically interpretable pathways x x x x x
Pathway activity estimates x x x x x
Pathway significance estimates x x x
ASSIGN offers a more comprehensive set of features compared with other existing approaches.
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perturbation experiments that do not fully represent the pathway
signatures in a disease environment and (iii) when one or more of
the pathways are deregulated, thus requiring significant adaptation
of the gene list, signature magnitudes and background expression
profile. Detailed descriptions of data generation and the results are
given in the Supplementary Materials.
3.6 Software implementation and application
ASSIGN is available as a Bioconductor package, written in the R
programming language and is freely available for download at
http://www.bioconductor.org/packages/release/bioc/html/ASSIGN.html.
As input, ASSIGN requires gene expression data from patient/test
samples, and a signature perturbation dataset or signature gene list.
When perturbation data are given, ASSIGN automatically generates
pathway signatures based on the raw gene expression data from one
or more perturbations. When signature perturbation datasets are un-
available, the user can provide predetermined signature gene lists
(e.g. from public databases, prior differential expression experi-
ments). ASSIGN outputs a matrix of signature strengths for each
sample and the prior/posterior signature gene lists and magnitude
changes. The software also provides the user with output from a
complete internal cross-validation on the perturbation data, MCMC
posterior convergence diagnostics and an evaluation of classification
accuracy when patient labels are provided by the user. The user can
specify model parameters/features such as background adaptation,
signature adaptation and regularization of signature strength. The
model specification options for the analyses in this study are listed in
Supplementary Table S3.
4 Results
To overcome challenges from pathway ‘cross-talk’ and heterogen-
eity from biological and technical sources, we developed the
ASSIGN toolkit that allows for flexible profiling of multiple corre-
lated signatures into specific disease, tissue and patient contexts.
Here, we demonstrate the features of ASSIGN using simulation,
cross validation and several publicly available genomic datasets. In
Section 4.1, we use three simulated scenarios to evaluate the model’s
abilities to estimate pathway-activation status and filter irrelevant
genes. In Sections 4.2 and 4.3, we illustrate ASSIGN’s ability to
account for context-specific background levels and to crosstalk
among multiple pathways. In Section 4.4, we evaluate the effective-
ness of ASSIGN to overcome cross-tissue and cross-platform obs-
tacles to estimates pathway activity in a large breast carcinoma
dataset. In Section 4.5, we adapt curated signatures of DNA damage
response pathways to estimate pathway signature strength in liver
profiling samples. In these sections we compare ASSIGN in multiple
contexts with existing methods such as GSEA, ssGSEA, BFRM and
FacPad and demonstrate a general advantage of ASSIGN over these
existing approaches.
4.1 Simulation studies
We conducted a simulation study to evaluate the performance of
ASSIGN under three scenarios to test the ability of ASSIGN to ef-
fectively estimate background, signature and activity profiles.
Details regarding data generation for each scenario are given in
Supplementary Materials. In the first simulation scenario, we eval-
uated ASSIGN’s ability to estimate a pathway’s activity when path-
way signatures are known a priori. ASSIGN accurately estimated
the activation level of the pathways (Supplementary Table S4A). In
the second simulation scenario, we attempted to estimate signatures
obtained from pathway perturbation experiments that require con-
text-specific adaptation. ASSIGN was able to closely estimate the
posterior mean of the activation levels and accurately estimate the
correct posterior means of the background and the signature
(Supplementary Table S4B). Here, we observed that 91% of the
insignificant genes and 98% of the significant genes were respect-
ively dropped from or added to the posterior (Supplementary
Fig. S2). In the third simulated scenario, we showed that ASSIGN
was capable of detecting more than one activated pathway
(Supplementary Table S4C). Furthermore, we discovered that know-
ledge of the regulation status of only 10 genes out of 250 total
significant genes was sufficient to overcome the sign-flipping issue
and correctly estimate a pathway activation status.
4.2 Profiling of interconnected oncogenic pathways
Many pathway analysis methods use a single-pathway approach
where the pathways are profiled independently. However, because
pathways interact with each other as part of complex biological sys-
tems, analyzing multiple pathways simultaneously provides better in-
sight into pathway function and activity. We validated our multiple-
pathway-based model by predicting activity of five previously pub-
lished oncogenic pathways (b-catenin, E2F3, MYC, RAS, SRC) in
human cell lines (Bild et al., 2006). In these signatures, about 17% of
the genes exhibit significant expression changes in more than one
pathway and also exhibit high correlation across the pathway gene
expression signatures (Supplementary Table S5).We used ASSIGN to
estimate pathway activity profiles for all five pathway sets via cross
validation. ASSIGN consistently predicted pathway activity profiles
accurately in all of these samples (Fig. 2A). In contrast, the single-
pathway BFRM approach (West, 2003) and FacPad incorrectly esti-
mated pathway activity profiles for four of the five pathways (Fig.
2B, C). Consequently, the false-positive pathway activation profiles
from these approaches could interfere with clinical decisions for se-
lecting the appropriate targeted therapies for cancer patients.
4.3 Adapting background levels across heterogeneous
samples
To further evaluate the importance of correcting for context-specific
baseline expression levels, we estimated pathway activity for the
EGFR and MEK co-activated RNA-Seq samples using the EGFR
and MEK pathway signatures profiled using RNA-Seq. We also
included a previously published PI3K signature that was generated
in a different cell type (lung epithelial cells compared with mammary
epithelial cells) using a microarray profiling technology. To validate
the adaptive background feature of ASSIGN, we compared three
ASSIGN model settings: (i) background (i.e. expression levels when
no pathways are active) fixed to the observed values in the control
samples of the EGFR/MEK pathway coactivated experiment; (ii)
background fixed to the value in the control samples of the PI3K
activation experiment; (iii) background fixed as in (ii) but allowing
for ASSIGN background estimation. We observed that the pathway
activation level was correctly estimated in model (i), which included
the correct background and (iii) with the ASSIGN adapted back-
ground, but not in (ii) with a non-adaptive incorrect background
(Supplementary Fig. S3). The posterior mean of B estimated in
model (iii) converged almost exactly to the true values (Cor.¼0.99),
whereas the background values used in model (ii) deviate from
the true values (Cor.¼0.60). Thus, the ASSIGN model (iii) with
adaptive background correctly estimates EGFR and MEK pathway
activity in EGFR and MEK co-activated samples even when the
background is unknown (Fig. 3). In these samples, we observed that
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the EGFR signature is strong in the EGFR-only samples and the
MEK signature is strong in the MEK-only samples. Both EGFR and
MEK are upregulated in the EGFRþMEK samples, with EGFR sig-
nal being overall lower, potentially due to stronger negative feed-
back on the pathway with concurrent activation of EGFR and MEK
(Avraham and Yarden, 2011; Klinger et al., 2013). For the sake of
comparison across methods, we applied the FacPad and BFRM
methods to these scenarios. FacPad requires a baseline level for each
sample and takes the ratio of treated samples and control samples as
input. When true baseline information of the EGFR and MEK coac-
tivated samples was not available, FacPad failed to estimate the
correct pathway activation level (Fig. 3). BFRM correctly estimated
the EGFR and MEK pathways in the EGFR and MEK coactivated
samples when the background in the patient samples perfectly
matched the training samples, albeit slightly less significantly than
ASSIGN. However, BFRM does not adjust for the background
expression level across platforms, and thus estimated elevated PI3K
levels in the EGFR and MEK samples (Fig. 3).
4.4 Cross-platform and cross-tissue pathway profiling
We examined activity levels for our RNA-seq based EGFR and
MEK pathways combined with a previously published PI3K signa-
ture generated on a different cell type and on a microarray profiling
technology. We used ASSIGN to estimate pathway activation status
in RNA-seq data from breast carcinomas and matched adjacent nor-
mal breast samples from TCGA. In addition, we compared pathway
activation in the breast carcinomas based on four molecular sub-
types: basal-like, luminal A, luminal B and Her2 (Supplementary
Fig. S4). For all three pathways, ASSIGN consistently found known
pathway-molecular subtype relationships confirmed by other studies
and outperformed BFRM and FacPad (Cheang et al., 2008; Hoeflich
et al., 2009; Lo´pez-Knowles et al., 2010; Moestue et al., 2013). All
approaches estimated significantly higher EGFR activity in tumor
samples in general as well as in all four subtypes of breast cancer
compared with normal tissue (Table 2A). ASSIGN correctly pre-
dicted MEK activity to be higher in the basal-like subtype and PI3K
activity to be higher both in basal-like and Her2 subtype than nor-
mal tissues (Table 2B, C). BFRM failed to recognize higher MEK ac-
tivity and higher PI3K activity in basal-like subtypes (Table 2B, C).
FacPad incorrectly predicted MEK activities to be significantly lower
than normal tissue (Table 2B; Supplementary Fig. S4).
4.5 Context-specific signature predictions in individual
samples
To evaluate ASSIGN’s signature adaptation features and single sam-
ple prediction abilities, we investigated pathway activation status in
liver samples from Rattus norvegicus exposed to genotoxic or
non-genotoxic carcinogens. We estimated how well we could use
curated pathway signatures from existing databases to predict geno-
toxicity of the carcinogenic compounds. For validation purpose,
we used the outcome of an Ames Salmonella test as a proxy for
genotoxicity (Mortelmans and Zeiger, 2000) available through
CPDB (Fitzpatrick, 2008) for the carcinogenic compounds under con-
sideration. In this study, we focused on the association of the activity
Fig. 2. Oncogenic pathway activity prediction via cross-validation. Predicted
pathway activity for (A) ASSIGN, (B) BFRM and (C) FacPad. Activation levels
of two oncogenic pathways (Bcat, Src) were estimated for cell lines with one
of five pathways activated (b-catenin, E2F3, MYC, RAS, SRC). The ASSIGN
and BFRM values range between zero (inactive pathway) and one (active
pathway). FacPad was designed for relative pathway activation comparisons
and activation levels can range from negative infinity to infinity
Fig. 3. Pathway activity prediction using cross-platform generated pathway
signatures. Comparison of ASSIGN, BFRM and FacPad predicted EGFR (A),
MEK (B) and PI3K (C) pathway activity in EGFR, MEK and EGFRþMEK acti-
vated RNA-Seq samples. EGFR and MEK pathway signatures were profiled
via RNA-Seq, whereas PI3K pathway signature was profiled via microarray.
ASSIGN detected two pathways (EGFR and MEK) activated at the same time
in the EGFRþMEK samples and correctly predicted that the PI3K pathway
was inactive, whereas BFRM and FacPad estimated PI3K pathway activation
incorrectly. FacPad also estimated active pathways as inactive and inactive
pathways as active (so called ‘sign-flipping’. See Section 3)
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level of DNA damage response/repair pathways with genotoxic car-
cinogen exposures. Among DNA damage response/repair pathways
from the MSigDB database, 9 pathways were identified as differen-
tially activated between the two groups (genotoxic versus non-geno-
toxic) by at least two of four approaches: ASSIGN, GSEA, ssGSEA
and FacPad (Table 3). BFRM was not included in this analysis be-
cause it requires gene expression profiling data from pathway per-
turbation experiments to train its model (these are not available here).
We applied GSEA, ssGSEA and FacPad to test the enrichment of
DNA damage/repair pathways in genotoxic group and to validate
ASSIGN predictions. FacPad yielded results largely inconsistent with
the other methods; FacPad often produced mean differences between
two groups that were in opposite directions than the other
approaches. Although GSEA and ssGSEA approaches yielded results
similar to ASSIGN, we note that ASSIGN did not require genotoxic
status to estimate the pathway activation level. Furthermore, in con-
trast to GSEA, ssGSEA and FacPad, ASSIGN is able to estimate abso-
lute pathway activity for each individual sample (Supplementary
Table S6). ssGSEA outputs an enrichment score for each sample, but
this score is on a relative (not absolute) scale. Therefore, pathway en-
richment/activation can only be determined in contexts containing
multiple control samples (Supplementary Table S7). The ASSIGN pre-
dictions of genotoxic carcinogen exposure using the KEGG P53 sig-
naling pathway in rat samples closely matched the genotoxicity labels
from the bacterial assays with AUC¼0.91 (Figure 4-A and 4-B).
4.5.1 Context-specific signatures
We further examined the adaptive pathway KEGG P53 signature
estimated by ASSIGN. The predefined signature of the KEGG P53
signaling pathway from MSigDB is a curated gene set for Homo
sapiens. ASSIGN adapts this signature to R. norvegicus when
predicting the pathway activity level in rat samples. For the adaptive
signature of this pathway, we observed that 65% of the genes in the
KEGG P53 signaling pathway were dropped out from the significant
gene list (posterior probability <0.90) (Supplementary Table S7).
In addition, for the genes retained in the list, although the magnitude
of gene expression level is not provided in the predefined signature, it
was estimated and adapted to the rat samples (Supplementary Table
S7). We plotted a heatmap, ordering the samples by the activity level
of the context-specific R. norvegicus KEGG P53 signaling pathway.
The gene expression profiles of those 36 rat samples were naturally
clustered by pathway activity predicted by ASSIGN (Fig. 4C).
5 Conclusions and Discussion
We have developed the ASSIGN approach for simultaneously
determining the strengths of multiple molecular signatures in patient
samples. Our ASSIGN framework is specifically designed for cases
where the signatures or relevant signature gene lists are known
a priori. ASSIGN does not accommodate situations where signatures
are completely unknown. ASSIGN uses sparse Bayesian regression
and factor analysis approaches to simultaneously profile multiple
pathway signatures. ASSIGN is a flexible toolkit that allows for sig-
natures in the form of gene sets, gene sets with direction and magni-
tudes or signatures extracted directly from profiling data. ASSIGN
also allows for adapting the background and the signatures to better
accommodate specific tissues, biological systems or disease contexts.
We have demonstrated the usefulness of our approach in mul-
tiple simulated and real-data examples and showed that ASSIGN
performs favorably in these datasets compared with other existing
approaches. For example, because ASSIGN evaluates multiple path-
way signatures simultaneously, it accounts for confounding events
between interactive pathways. Here, we applied ASSIGN to five
highly correlated oncogenic pathways and compared results with
BFRM, a single pathway-based approach. Although, BFRM
achieves similar sensitivity to ASSIGN, BFRM has much lower spe-
cificity. In addition, ASSIGN can use either curated pathway signa-
ture gene lists or perturbation signatures in a flexible way. Most
supervised learning methods, such as BFRM, require perturbation
datasets as input. GSEA and FacPad can only use curated pathway
gene lists. For pathway signature profiling, the selection of multiple
pathways is based on the biological knowledge of pathway
Table 2. Comparison of predicted pathway activity in breast carcin-










0.20 (<0.001) 0.13 (<0.001) 1.81 (<0.001)
Basal versus
Normal
0.28 (<0.001) 0.13 (<0.001) 1.68 (<0.001)
Her2 versus
Normal
0.23 (<0.001) 0.11 (<0.001) 1.54 (<0.001)
Luminal A versus
Normal
0.09 (<0.001) 0.07 (<0.001) 0.98 (<0.001)
Luminal B versus
Normal
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Basal versus
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0.02 (0.094) "0.02 (0.115) 0.30 (0.033)
Pathway activity comparison between breast carcinoma and normal tissues,
and breast carcinoma subtypes (Basal, Her2, Luminal A, Luminal B) and nor-
mal tissues using two-sample t-test. P-values of t-tests are listed in the table.
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interaction. However, we recommend a maximum of about a dozen
of correlated pathways in ASSIGN to avoid multicollinearity and
unidentifiability issues of the model.
The adaptive background feature of ASSIGN allows for the esti-
mation of absolute pathway activity levels in a biologically interpret-
able manner (ranging between 0 and 1). No existing factor analysis
approach or supervised learning approach accommodates this feature,
and thus can only achieve relative activation status. The enrichment
scores estimated by ssGSEA do not have biological meaning unless
compared with control samples for relative pathway strength. GSEA
estimates one overall enrichment score, but does not predict for indi-
vidual samples. Furthermore, ASSIGN allows for the refinement and
adaptation of pathway signatures within a dataset, in contrast to
other regression-based or supervised learning algorithms in which the
predetermined pathway signature is static (Pirooznia et al., 2008;
Ringne´r et al., 2002). This unique feature not only reduces the bias of
pathway strength estimation, but also curates pathway signatures to
be cell- or tissue-specific future applications.
In addition to pathway activation level estimation, ASSIGN can
be used to predict patients’ drug response, carcinogen exposure,
pathogen immune response on the basis of gene expression signature
strength. The input data of ASSIGN is assumed to follow a normal
distribution. To accommodate to different types of omic data such as
methylation microarray data or SNP array data, a more generalized
model may need to be developed in the future. In addition, in future
work we plan to allow for multiple background profiles in the patient
dataset, whereas the current version of ASSIGN only allows for a sin-
gle baseline expression profile. We also hope to evaluate extensions of
ASSIGN to integrate multi-omic data types and to better accommo-
date the discrete nature of sequencing data. Overall, ASSIGN results
in more biologically interpretable pathway activation profiles that are
adapted to specific tissues or disease contexts, as opposed to more
rigid and less interpretable profiles from previous approaches.
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Table 3. Comparison of pathway activity between genotoxic and non-genotoxic groups reported in P-values
Pathways ASSIGN GSEA ssGSEA FacPad
AMUNDSON_DNA_DAMAGE_RESPONSE_TP53 <0.001 0.027 <0.001 0.279
AMUNDSON_GENOTOXIC_SIGNATURE 0.032 0.074 0.002 0.290
KEGG_P53_SIGNALING_PATHWAY <0.001 0.077 <0.001 0.464
KYNG_DNA_DAMAGE_BY_4NQO 0.041 0.198 0.027 0.159
KYNG_DNA_DAMAGE_BY_4NQO_OR_GAMMA_RADIATION 0.695 0.054 0.014 0.001
KYNG_DNA_DAMAGE_BY_GAMMA_AND_UV_RADIATION 0.002 0.042 0.001 0.024
KYNG_DNA_DAMAGE_BY_UV 0.024 0.117 0.023 0.320
KYNG_DNA_DAMAGE_DN 0.014 0.002 <0.001 0.221
KYNG_DNA_DAMAGE_UP 0.009 0.058 0.038 0.703
Pathway activity compared between genotoxic and non-genotoxic groups (two sample t-test for ASSIGN, FacPad and ssGSEA; Kolomogorov–Smirnov test
for GSEA). The results were mostly consistent among the ASSIGN, GSEA and ssGSEA approaches, but mostly inconsistent with FacPac approach. DNA damage
response/repair pathways were significantly differentially activated (P-value) between two groups for at least two approaches.
Fig. 4. KEGG P53 signaling pathway signature in tissues exposed to carcino-
gens. (A) ASSIGN predicted pathway activity in rat liver tissues exposed to
non-genotoxic or genotoxic carcinogens. The boxplot exhibits an association
between genotoxic carcinogen exposure and P53 signaling pathway activa-
tion. (B) ROC curve for ASSIGN predicted signature strengths of the KEGG
P53 signaling pathway. The corresponding area under the curve (AUC) is
0.911, suggesting an excellent model predictive ability. (C) Heatmap of 43
predefined P53 signaling pathway genes in 36 rat liver samples. Each row
represents a gene and each column represents a sample. The color bar above
the heatmap represents the treatment labels for each corresponding sample
(orange: genotoxic; grey: non-genotoxic). The bar plot above the heatmap is
the ASSIGN predicted signature strength for each corresponding sample.
The bar plot on the left is the ASSIGN predicted posterior signature (green:
gene included in the posterior signature; grey: gene not included)
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Abstract
Motivation: The Cancer Genome Atlas (TCGA) RNA-Sequencing data are used widely for research.
TCGA provides ‘Level 3’ data, which have been processed using a pipeline specific to that resource.
However, we have found using experimentally derived data that this pipeline produces gene-
expression values that vary considerably across biological replicates. In addition, some RNA-
Sequencing analysis tools require integer-based read counts, which are not provided with the
Level 3 data. As an alternative, we have reprocessed the data for 9264 tumor and 741 normal sam-
ples across 24 cancer types using the Rsubread package. We have also collated corresponding clin-
ical data for these samples. We provide these data as a community resource.
Results: We compared TCGA samples processed using either pipeline and found that the
Rsubread pipeline produced fewer zero-expression genes and more consistent expression levels
across replicate samples than the TCGA pipeline. Additionally, we used a genomic-signature ap-
proach to estimate HER2 (ERBB2) activation status for 662 breast-tumor samples and found that
the Rsubread data resulted in stronger predictions of HER2 pathway activity. Finally, we used data
from both pipelines to classify 575 lung cancer samples based on histological type. This analysis
identified various non-coding RNA that may influence lung-cancer histology.
Availability and implementation: The RNA-Sequencing and clinical data can be downloaded from
Gene Expression Omnibus (accession number GSE62944). Scripts and code that were used to pro-
cess and analyze the data are available from https://github.com/srp33/TCGA_RNASeq_Clinical.
Contact: stephen_piccolo@byu.edu or andreab@genetics.utah.edu
Supplementary information: Supplementary material is available at Bioinformatics online.
1 Introduction
The Cancer Genome Atlas Research Network has profiled thou-
sands of human tumors to discover various types of molecular-level
aberrations that occur within tumors. Researchers have used these
data to derive new insights about tumorigenesis and to validate and
inform experimental findings (The Cancer Genome Atlas Research
Network et al., 2013). To facilitate such analyses, The Cancer
Genome Atlas (TCGA) provides ‘Level 3’ RNA-Sequencing
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(RNA-Seq) data, which have been aligned to the reference genome
using MapSplice (Wang et al., 2010), quantified at the gene and
transcript levels using RSEM (Li and Dewey, 2011) and standar-
dized using upper-quartile normalization (Bullard et al., 2010; Li
and Dewey, 2011; Wang et al., 2010). However, the use of these
data comes with some caveats. First, some analytic tools designed
specifically for RNA-Seq data—for example, DESeq2 (Love et al.,
2014)—require the user to input integer-based read counts, yet
Level 3 read counts are represented as non-integer numbers. Second,
the upper-quartile normalization method scales gene counts by the
upper-quartile value of the non-zero distribution; however, when a
sample has a relatively high number of zero counts or genes with ex-
tremely high read counts, the value distributions may vary consider-
ably across samples (Dillies et al., 2013). Third, when researchers
seek to compare the TCGA Level 3 data against clinical covariates
and outcomes, additional processing steps are necessary to match
RNA-Seq identifiers to the clinical data. Users without computa-
tional training may face difficulty performing these steps, and scien-
tists may duplicate each other’s efforts.
The TCGA consortium also provides the RNA-Seq data in raw
form. Thus it is possible for researchers to reprocess the data using
alternative computational pipelines. We obtained raw sequencing
data for 9264 tumor samples and 741 normal samples across 24
cancer types (Table 1) and reprocessed the data using the Subread al-
gorithm (Liao et al., 2014), which shows high concordance with
other existing methods regarding assignment of reads to genes but
takes a relatively short time for processing (SEQC/MAQC-III
Consortium, 2014). RNA transcripts often span multiple exon-exon
junctions, making it challenging for aligners to map reads that are
smaller than the transcript length. Rsubread’s ‘vote-and-seed’ read-
mapping technique addresses this problem by breaking the reads
into relatively small segments, mapping the segments to the refer-
ence genome and identifying locations where adjacent segments map
to different exons. This approach has been shown to be more accur-
ate in mapping junction reads than other aligners, including
MapSplice (Liao et al., 2013). The Rsubread package, which imple-
ments the Subread algorithm, is convenient for this task because: (i)
it can be applied to both single- and paired-end reads; (ii) it is con-
siderably faster and requires less computer memory than many other
methods and (iii) it requires no external software packages for pro-
cessing, whereas many other packages require a series of steps that
span multiple packages.
We used the featureCounts function within the Rsubread pack-
age to summarize the data to integer-based, gene-level read counts,
and we calculated two types of normalized value: fragments per
kilobase of exon per million reads mapped (FPKM) and transcripts
per million (TPM) (Li and Dewey, 2011; Mortazavi et al., 2008;
Wagner et al., 2012). In this pipeline, the FPKM and TPM values
are calculated using the total number of mapped reads and the total
number of non-overlapping exonic basepairs. Both FPKM and TPM
methods account for the length of genomic features. FPKM corrects
for the number of reads that have been sequenced, and TPM ac-
counts for the average number of mapped bases per read. FPKM val-
ues are used widely, whereas TPM values have been shown to meet
the invariant average criterion and thus may be more comparable
across samples (Wagner et al., 2012). Importantly, FPKM and TPM
are calculated using only data from an individual RNA-Seq sample;
thus adding new samples to the dataset will not require changes to
the existing expression values; such an approach is crucial for preci-
sion-medicine applications and for integrating data across technol-
ogy platforms (Piccolo et al., 2012, 2013). Furthermore, because we
have provided raw counts, it is possible for others to normalize the
data using other methods with relative ease. We have made these
data publicly available along with all clinical variables provided by
TCGA for these samples. We have also aligned the RNA-Seq sample
identifiers with the clinical identifiers.
Table 1. Cancer types and total number of samples
Cancer name Abbreviated cancer name Samples included
Adrenocortical carcinoma ACC 79
Bladder urothelial carcinoma BLCA 414
Breast invasive carcinoma BRCA 1119
Cervical squamous cell carcinoma and endocervical adenocarconoma CESC 306
Colon adenocarcinoma COAD 483
Lymphoid neoplasm diffuse large B-cell lymphoma DLBC 48
Glioblastoma multiforme GBM 170
Head and neck squamous cell carcinoma HNSC 504
Kidney chromophobe KICH 66
Kidney renal clear cell carcinoma KIRC 542
Kidney renal papillary cell carcinoma KIRP 291
Acute myeloid leukemia LAML 178
Brain lower grade glioma LGG 532
Liver hepatocellular carcinoma LIHC 374
Lung adenocarcinoma LUAD 541
Lung squamous cell carcinoma LUSC 502
Ovarian serous cystadenocarcinoma OV 430
Prostate adenocarcinoma PRAD 502
Rectum adenocarcinoma READ 167
Skin cutaneous melanoma SKCM 472
Stomach adenocarcinoma STAD 420
Thyroid carcinoma THCA 513
Uterine corpus endometrial carcinoma UCEC 554
Uterine carcinoma UCS 57
A total of 9264 tumor samples across 24 cancer types are included in the database.
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2.1 HER2 gene-expression profiling data
Before analyzing TCGA data, we generated an experimental dataset
that represented the effects of HER2 (ERBB2) overexpression in
breast cancer cells. Using human mammary epithelial cells
(HMECs), we produced five replicates, in which the HER2 protein
had been experimentally activated, and 12 control green fluorescent
protein (GFP) replicates. We used recombinant adenovirus to over-
express HER2 (Vector Biolabs) and GFP in the HMECs. The
HMECs were grown in serum-free WIT-P media (Stemgent) and
were starved of growth factors for 36 h prior to infection. HER2-ex-
pressing or GFP-expressing adenovirus (MOI 500) were added to
HMEC cells in conditioned media and incubated with the cells for
18 h. Cells were washed with phosphate buffered saline, scraped
into RNAlater (Ambion), and RNA was extracted from pelleted
cells using an RNeasy kit (Qiagen) with DNase. To ensure that com-
ponents were being expressed, we created lysates of HER2-adeno-
virus-vector and GFP-adenovirus-vector infected HMEC cells and
analyzed these lysates for expression of HER2-pathway protein
components by sodium dodecyl sulphate–polyacrylamide gel elec-
trophoresis/Western blot. HER2 overexpression and activity was
confirmed by Western blotting for HER2 and for activated HER2
(phospho-Tyr1173-HER2, Supplementary Fig. S1). cDNA libraries
were prepared from the extracted RNA using the Illumina Stranded
TruSeq protocol and then sequenced with the Illumina HiSeq 2000
sequencing platform with six samples per lane. Single-end reads of
101 base pairs were generated. This dataset is available on Gene
Expression Omnibus via accession number GSE62820.
2.2 TCGA data acquisition
We downloaded TCGA Level 3 data via the Synapse portal for
12 cancer types (https://www.synapse.org/#!Synapse:syn1695324).
This included 3468 samples that had been preprocessed using
TCGA’s standard pipeline.
To reprocess TCGA data with Rsubread, we downloaded
FASTQ formatted files for all available TCGA tumor samples via
the National Cancer Institute’s Cancer Genomics Hub (Wilks et al.,
2014). This included a total of 9264 tumor samples across 24 cancer
types (Table 1). Some patient samples were sequenced multiple
times; in these cases, we included each replicate.
We downloaded TCGA clinical data in ‘Biotab’ format on May
20, 2015 from the TCGA data portal (https://tcga-data.nci.nih.gov/
tcga/dataAccessMatrix.htm) and extracted all reported clinical vari-
ables from the nationwidechildrens.org_clinical_patient_[cancer
TypeAbbreviatedInLowerCase].txt files. In these files, 12-character
patient identifiers were used, whereas the RNA-Seq sample identi-
fiers were longer. To make it easier to integrate these two data sour-
ces, we converted the short IDs to full IDs by matching the
‘bcr_patient_barcode’ values in the clinical files. For patients who
had multiple RNA-Seq replicates, we provide multiple columns in
the clinical data file. We set values as ‘NA’ when no information
was reported in the clinical files for a given patient. If there were
multiple sequences available for a tumor sample, we duplicated the
clinical variables available for that sample. In total, we included 548
clinical variables.
2.3 Data processing and normalization
For our HER2 expression-profiling data, we calculated gene-level
values using the same steps that the TCGA consortium uses to pro-
duce ‘Level 3’ values. The reference data, Perl scripts and parameters
used in this pipeline are described here: https://cghub.ucsc.edu/docs/
tcga/UNC_mRNAseq_summary.pdf. In some cases, the software
versions specified in the above document were unable to handle sin-
gle-end reads. In these cases, we used the latest versions of these soft-
ware tools that were able to handle single-end reads. Below we list
these versions:
• MapSplice v 12_07 (Wang et al., 2010)
• RSEM v1.2.12 (Li and Dewey, 2011)
• UBU v1.2 (https://github.com/mozack/ubu/)
• Picard-tools v1.82 (http://picard.sourceforge.net)
• BedTools v2.17.0 (Quinlan and Hall, 2010)
For our HER2 data and for the samples from TCGA, we used
the Rsubread package (version v1.14.2; Liao et al., 2014) to align
the reads and to produce gene-level summarized values. We used the
UCSC hg19 reference for alignment and the corresponding gene an-
notation format file available from http://support.illumina.com/
sequencing/sequencing_software/igenome.html. Within this pipeline,
we obtained integer-based gene counts using the featureCounts func-
tion in the Rsubread package (Liao et al., 2014). We used the limma
(version 3.20.9; Smyth, 2004) and edgeR (version v3.6.8;
Nikolayeva and Robinson, 2014; Robinson et al., 2010) packages to
calculate FPKM values (Li and Dewey, 2011) and a custom script to
convert FPKM to TPM values (Li and Dewey, 2011; Wagner et al.,
2012). We used R version 3.1.0 and Bioconductor version 2.14
(Gentleman et al., 2004; R Core Team, 2014; http://www.R-project.
org/). When evaluating pre-normalized gene counts, we used the
‘expected_count’ column in the ‘.genes.results’ files generated by
RSEM, and Rsubread’s raw, integer-based gene counts. All pro-
cessed TCGA data can be accessed on Gene Expression Omnibus
via accession number GSE62944. This includes integer-based gene
counts and FPKM and TPM values as well as clinical data.
2.4 Statistical procedures
When comparing gene-expression values between groups in this
study, we calculated the standardized mean difference using Hedges’
formula (Hedges, 1981, 1985). We used the coefficient of variation
(CV) to assess variability. We used the Random Forests classifica-
tion algorithm implemented in the caret package (Kuhn, 2008).
The data-processing pipelines and analysis scripts that we used
for this manuscript are available from https://github.com/srp33/
TCGA_RNASeq_Clinical.
3 Results
3.1 Evaluation of biological replicates
Our initial goal was to generate a gene-expression signature repre-
senting HER2 activation and to use that signature to identify breast
tumors in TCGA where the HER2 pathway was active. For consist-
ency with TCGA, we initially processed the RNA-Seq signature data
using the same pipeline used by the TCGA consortium (see
Materials and Methods). However, upon examining these data, we
observed inconsistencies across our biological replicates. For ex-
ample, as illustrated in Figure 1, we found that some replicates ex-
hibited considerably different patterns of expression for genes that
showed the greatest differences in expression between HER2-active
cells and GFP controls. Concerned that such inconsistencies could
reduce the effectiveness of our signature-based predictions, we
examined the data further and explored the Rsubread pipeline as an
alternative.
We hypothesized that the inconsistencies we observed in our bio-
logical replicates may have resulted from differences in the total
Alternative preprocessing of RNA-Seq data 3









number of mapped reads, from genes expressed at extremely high
levels or from differences in the number of zero-count genes per
sample. Others have described these factors as potential limitations
of the upper-quartile normalization step used in the TCGA Level 3
processing pipeline (Dillies et al., 2013). Accordingly, we repro-
cessed the data using Rsubread and performed various analyses to
understand the effects of these variables for data processed using ei-
ther pipeline. In addition, we performed various analyses to com-
pare the performance of the two datasets in various biomedical
research contexts (Supplementary Table S1).
3.2 Raw gene count analysis
Initially, we compared raw (non-normalized) gene counts between
the TCGA Level 3 and Rsubread processing pipelines for our HER2
(n¼5) and control (n¼12) replicates. The TCGA Level 3 pipeline
produces expected counts as floating point (non-integer) numbers,
whereas Rsubread produces integer-based gene counts, which repre-
sent the number of mapped reads per gene. For both pipelines, the
HER2 gene counts were significantly overexpressed in HER2 acti-
vated cells relative to control samples (Supplementary Fig. S2).
However, the difference in expression between HER2-activated cells
and controls was greater for the Rsubread data (standardized mean
difference for TCGA: 10.0; Rsubread: 23.8).
To explore these differences further, we compared the total num-
ber of mapped reads per sample between the two pipelines. For
HER2-activated samples, the total number of mapped reads was
much more variable for the TCGA Level 3 data than for the
Rsubread data (Fig. 2). Two of the HER2-activated samples—the
same samples (2 and 4) that showed visual differences in Figure 1—
had a considerably smaller number of total mapped reads when the
TCGA pipeline was used. Upon plotting the empirical cumulative
distribution of the total mapped reads per sample (Fig. 3 and
Supplementary Fig. S3), we observed that the same HER2-activated
samples showed different overall expression patterns, due to a rela-
tively high number of genes with zero read counts. These
observations suggest that Rsubread is less sensitive to differences in
library size and that it more consistently identifies genes expressed
at extremely low levels.
3.3 Normalized gene expression analysis
We observed similar findings for the normalized values produced
using either pipeline. The empirical cumulative distribution of total
normalized expression was more consistent for the Rsubread data
(FPKM and TPM) than for the TCGA Level 3 data (Supplementary
Fig. S4). HER2 gene-expression levels were less variable across the
replicates for the Rsubread values than for the Level 3 data (CV for
FPKM¼0.09; TPM¼0.06; Level 3¼0.30). Differences in expres-
sion between HER2 activated cells and controls were also greater
for the Rsubread data (standardized mean difference for
FPKM¼66.9; TPM¼67.2; Level 3¼25.8; see Supplementary Fig.
S4). In addition, across all genes for the control and HER2-activated
Fig. 1. Heat maps of normalized expression values for the 200 genes most differentially expressed between HER2-activated HMECs (n¼5) and GFP-treated
controls (n¼12). Each column in the heat maps represents data for a given HMEC replicate. Each row represents data for a given gene
Fig. 2. Total mapped reads per sample for data processed using the TCGA
Level 3 and Rsubread pipelines. For the TCGA Level 3 pipeline, the number of
mapped reads varied widely for the HER2 samples, and samples 2 and 4 (see
Fig. 1) had a considerably lower number of mapped reads. In contrast, the
number of mapped reads for Rsubreadwas consistent across the samples
4 M.Rahman et al.









replicates, the coefficients of variation were smaller for the Rsubread
processed data than for the TCGA Level 3 data (Supplementary Fig.
S5). These observations remained consistent, even if we excluded the
two HER2 replicates that showed different gene-count distributions in
the TCGA Level 3 data (Supplementary Table S2).
We calculated the number of zero-expression genes per GFP sam-
ple using the genes that overlap between the TCGA Level 3
and Rsubread TPM data. The Level 3 data contained a higher number
of zero-expressing genes per GFP replicate (Level 3 median: 4452;
Rsubread TPM: 4174). For each gene that had at least one zero value
across the replicates, we calculated the number of samples that had a
zero value for a given gene. The average was 7.50 (out of 12) for
TCGA Level 3 and 8.92 for Rsubread. Although the Level 3 samples
had a higher overall number of zero values across all genes
(Supplementary Fig. S6), these values were less consistent for a given
gene. These findings suggest that the alignment, count estimation and/
or upper-quartile normalization steps used in the Level 3 pipeline lead
to variability across the replicates and that the Rsubread FPKM and
TPM values are more consistent across replicates.
Having observed these patterns in our replicates, we processed
9264 RNA-Seq samples from TCGA using the Rsubread package.
We performed various comparative analyses using the samples that
overlapped with the Level 3 data that had been distributed via the
Pan Cancer 12 project (The Cancer Genome Atlas Research
Network et al., 2013). We limited our comparative analyses to the
genes (n¼19584) and samples (n¼3380) that overlapped between
these datasets. Across all samples, the number of zero-count genes
was significantly higher in the TCGA Level 3 data than in the
Rsubread data, (t-test P value<0.001; Level 3 median¼2742.5;
Rsubread TPM¼1910.0; see Supplementary Fig. S7). In addition,
we calculated Pearson’s correlation coefficients between replicates
for the 13 patients that were common between TCGA PANCAN12
and our Rsubread TPM data (Supplementary Table S3 and Fig. S8).
Across the replicates, the Pearson’s correlation coefficients were
higher for the Rsubread processed replicates (median¼0.86) than
for the TCGA Level 3 replicates (median¼0.79).
3.4. Downstream analyses
Next, we used a sparse binary factor regression method (West et al.,
2001) to derive a gene-expression signature that would predict
whether the HER2 pathway was active in a given TCGA breast-
tumor sample. This technique results in a probabilistic estimate
for each tumor sample that indicates whether the pathway is active.
We applied this approach to data from both processing pipelines
and compared the estimates of HER2 pathway activity be-
tween tumor samples that had been confirmed via immunohisto-
chemistry to be HER2 positive (n¼149) or negative (n¼513).
For both data-processing pipelines, the probabilistic estimates of
HER2 pathway activity were significantly higher for HER2-positive
versus HER2-negative samples (see Supplementary Fig. S9
and Table S4). However, the predictions for the Rsubread data
were less variable than for the TCGA Level 3 data (see
Supplementary Table S5), and the standardized mean difference be-
tween the groups was greater for the Rsubread data (TCGA Level 3:
0.44; Rsubread FPKM: 0.52; Rsubread TPM: 0.59). This finding
was robust to the exclusion of HER2 samples 2 and 4
(Supplementary Table S2). Thus, using an empirical approach to es-
timate HER2 pathway activity, the Rsubread data resulted in more
reliable and consistent conclusions when validated against
traditional methods.
As an additional test, we examined how well we could distin-
guish between lung adenocarcinoma (LUAD) and lung squamous
cell carcinoma (LUSC) samples in TCGA. This classification is clin-
ically important to guide personalized therapy based on the molecu-
lar subtypes (The Cancer Genome Atlas Research Network, 2012,
2014). We used the Random Forests classification algorithm
(Breiman, 2001) to identify gene-expression patterns that differ be-
tween these cancer types, and we performed 10-fold cross-validation
to estimate how accurately tumors of either cancer type could be
identified. For this analysis, we used TCGA Level 3 data and
Rsubread normalized (TPM) data for 575 tumor samples that over-
lapped between these datasets. We used receiver operating charac-
teristic (ROC) curves to assess classification accuracy and the
balance between sensitivity and specificity in making these predic-
tions. With the area under ROC curves (AUC) as a comparison met-
ric and a probability threshold of 0.5, both datasets resulted in
highly accurate predictions of lung-cancer histological type
(AUC¼0.999 for Rsubread; AUC¼0.985 for TCGA Level 3); how-
ever, the TCGA Level 3 data resulted in 28 (out of 575) incorrect
predictions, whereas the Rsubread data resulted in only 9 incorrect
predictions (Fig. 4).
Using the TCGA Level 3 data, Cline et al. (2013) suggested that
a subset of the LUSC samples were ‘discordant’ with the remaining
LUSC samples and exhibited ‘LUAD-like’ properties. Our Random
Forests predictions for the Level 3 data led to similar conclusions. In
contrast, when we use the Rsubread data, the ‘LUSC Discordant’
samples are classified mostly as ‘LUSC’. One difference between the
two datasets is that the TCGA Level 3 data contain values for
20 217 genes (after excluding genes that have zero variance across
all samples), whereas the Rsubread data contain values for 22 833
genes. Accordingly, we repeated the Random Forests classification
analysis and limited each dataset so that it included only the 19 453
genes that overlap between the two datasets. With this approach,
both datasets resulted in virtually identical results: most ‘LUSC
Discordant’ samples were classified as ‘LUAD’. We examined the
genes present in the Rsubread data but not in the TCGA Level 3
data and found various genes that show strong and consistent ex-
pression similarity between ‘LUSC Discordant’ and LUSC samples
(Supplementary Fig. S10). Expression patterns for these genes are
consistent and strong enough that they alter the Random Forests
classification results for the ‘LUSC Discordant’ samples. Although
these samples do exhibit expression patterns characteristic of LUAD
Fig. 3. Empirical cumulative distribution of total mapped reads using raw
gene counts. In all cases, the cumulative distributions were more consistent
for Rsubread than for the TCGA pipeline produced gene counts data. The ab-
errantly expressed samples in the TCGA data are the same samples (GFP
sample 4, HER2 samples 2 and 4) that showed visually different expression
patterns in the heat maps (see Fig. 1). GFP samples (n¼12) are represented
in blue and HER2 samples (n¼5) are represented in brown color
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for many genes, this analysis indicates that these samples should not
necessarily be classified as LUAD tumors. We observed this differ-
ence because the Rsubread data were processed using relatively re-
cent gene definitions; thus researchers who work with these data
may have a more complete picture of tumor biology.
4 Discussion
To our knowledge, this compendium of RNA-Seq tumor data is the
largest compiled to date. It includes 9264 tumor samples and 741
normal samples across 24 cancer types. These data offer an alterna-
tive to the lone pipeline used by the TCGA consortium. In contrast
to the TCGA data portal, which provides the RNA-Seq data in indi-
vidual files for each sample, we have compiled the Rsubread tumor
data into aggregate data files; thus it will be easier for researchers to
analyze the data and compare across cancer types. We have matched
these data to clinical variables to ease the process of examining rela-
tionships between these variables and gene-expression levels.
Different RNA-Seq processing pipelines differ considerably in
accuracy for quantifying gene-level expression values (Fonseca et al.,
2014). However, our goal was not to perform an exhaustive bench-
mark comparison across the many tools available for processing
RNA-Seq data, although others have shown that Rsubread performs
quite well in such benchmarks at quantifying gene-expression levels
(SEQC/MAQC-III Consortium, 2014). Rather our goals were to
provide a new community resource and to provide evidence that this
alternative dataset is of high quality and performs better in various
downstream analyses than the standard TCGA data. We have dem-
onstrated that Rsubread produces more consistent values across bio-
logical replicates, and we have provided evidence that our data lead
to more biologically relevant conclusions. Tens of thousands of
hours of computational processing time were necessary to compile
this dataset. Thus we also hope to prevent the need for other scien-
tists to invest similar resources.
Our dataset will be most useful to researchers who wish to com-
pare gene-level expression values across samples. Researchers who
wish to work with transcript- or exon-level values or who wish to
identify splice junctions may find the TCGA Level 3 data useful for
this purpose. Various Web-based portals exist for visualizing and
analyzing TCGA data. These include cBioPortal for Cancer
Genomics (Cerami et al., 2012; Gao et al., 2013) and the UCSC
Cancer Genomics Browser (Zhu et al., 2009). Our data could be
incorporated into these portals as an additional option for users
who wish to analyze raw gene counts or to use the FPKM and TPM
values that we provide.
We plan to update the data as more cancer types and tumor sam-
ples become available. We used open-source software to align and
normalize the data and have made our processing code publicly avail-
able. In addition, we used single-sample normalization techniques to
process the data. Thus, one can add new samples as they become
available without affecting the existing data. However, we emphasize
that it may still be necessary for researchers to correct for inter–sample
variation when comparing data across batches and cancer types.
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Fig. 4. Receiver operating characteristics (ROC) curves (in black) showing the balance between sensitivity and specificity in classifying TCGA lung adenocarci-
noma (LUAD) and lung squamous carcinoma (LUSC) samples using TCGA Level 3 and Rsubread pipeline processed RNA-Seq data. The gray shaded areas de-
note the confidence intervals associated with the ROC curve. The Rsubread data resulted in more accurate predictions than the TCGA Level 3 data when all the
genes for the respective pipelines were used
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Figure S1: Western blots showing expression levels for HER2-activated and GFP-
control cells. Lysates of HER2-adenovirus-vector (HER2) and green fluorescent protein 
(GFP) infected HMEC cells (18 hour infection) were generated, and expression of HER2 
protein components were visualized by SDS-PAGE/Western blot.  Western blots are 
shown for HER2 and phospho-Tyr1173-HER2 (P-HER2).  GAPDH signal is used as an 






















Figure S2: ERBB2 (HER2) raw gene counts produced using the TCGA and Rsubread 
pipelines. Log-transformed gene counts for the ERBB2 gene are shown for HER2-
activated human mammary epithelial cells (n=5) and for GFP-treated control cells 
(n=12). For HER2-activated cells, the values were much more variable for the TCGA 
pipeline processed gene counts data (coefficient of variation = 0.53) than for the 
Rsubread data (coefficient of variation = 0.15). For the GFP-treated cells the coefficients 
of variation were similar for both methods (TCGA  = 0.14, Rsubread = 0.18). In addition, 
the standardized mean difference between HER2-activated levels and GFP levels was 






















































Figure S3: Empirical cumulative distribution of total mapped reads using normalized 
gene counts. In all cases, the cumulative distributions were more consistent for the 
Rsubread data than for the TCGA Level 3 data. The outlier samples for the TCGA Level 
3 data are the same samples (GFP sample 4, HER2 samples 2 and 4) that showed visually 
different expression patterns in the heat maps (see Figure 1). GFP samples (n=12) are 



















































































































Figure S4: ERBB2 (HER2) normalized expression levels produced using the TCGA 
Level 3 and Rsubread pipelines. For HER2-activated cells, the values were more highly 
variable for the TCGA Level 3 data (coefficient of variation = 0.30) than for the 
Rsubread data (coefficient of variation for FPKM = 0.09,  coefficient of variation for 
TPM = 0.06). In addition, the standardized mean difference between HER2-activated 
level and control levels was greater for the Rsubread data (FPKM = 66.9, TPM = 67.2) 



































































Figure S5: Histogram of coefficients of variation across (A) control and (B) HER2 
overexpressed samples using 19584 common genes across the normalized gene 
expression datasets. In all cases there were some genes with high coefficient of variation 

























































































































































































































Figure S5(continued): number of genes and a lower median coefficient of variation than 






Figure S6: Distribution of number of zero expressing genes per HMEC GFP sample 
































Figure S7: The number of genes per sample that each pipeline determined to have zero 
expression. We limited this analysis to the TCGA tumor samples (n=3380) and genes 
(n=19,584) that were common between the TCGA Pan-Cancer 12 dataset and our Rsubread 
processed dataset. The TCGA Level 3 samples had a higher number of zeroes per sample than 
the Rsubread samples (p-value<0.001). Vertical lines show the median value for each pipeline 
(TCGA Level 3 = 2742.5, Rsubread TPM =1910). In addition, the TCGA Level 3 data 



















Figure S9:  Signature-based estimates of HER2 activation in TCGA breast-cancer 
samples (n = 662). We compared samples that had been identified via 
immunohistochemistry as either HER2 positive or negative. The standardized mean 
difference between HER2+ and HER2− samples was higher for the Rsubread processed 
data (FPKM = 0.52, TPM = 0.59) than for the TCGA Level 3 data (0.44). For visual 
consistency across the comparisons, we converted the signature predictions to rank-based 
































































Figure S10: A. Gene expression patterns for four genes (non-coding RNA) that are 
consistent with LUAD and LUSC histological classification. The “Discordant LUSC” 
samples were identified by Cline et al. as exhibiting LUAD-like properties; however, 
expression levels for these genes, which are not included in the TCGA Level 3 data, are 
consistent with histological classification. B. Histograms showing expression levels for 
MIR320A gene in LUAD, LUSC and discordant LUSC samples. Expression levels for 
















1. Supplementary Tables 
Table S1: Analyses scenarios, datasets and number of samples used in comparing TCGA 
Level 3 and Rsubread FPKM/TPM pipeline. 
Analysis Name Goal Datasets used Number of 
samples used  
Gene counts and 
normalized 
expression  
To compare gene level 
differences before and after 
normalization for the HER2 
gene 
Our experimental 
HMEC dataset  
17 
Effect of upper 
quartile 
normalization 
To compare the number of 
zero-expressed genes in the 




PanCan 12 Level 3 






To compare gene expression 
based signatures with 200 
genes 
Our experimental 





To predict HER2 status in 
TCGA BRCA samples where 
the HER2 status is known 
from immunohistochemistry 
TCGA BRCA 






To compare accuracy in 
classifying gene expression 
based lung adeno (LUAD) 
versus lung squamous 
carcinoma (LUSC) samples  






















Table S2: Comparison of standardized means 
Comparison of Hedge’s standardized mean differences with all HMEC samples and with 
2 HMEC outlier samples removed. For the Rsubread data, we used TPM values. 
 All samples included 
[GFP n=12 and 
HER2 n=5] 
Outlier samples removed 








25.8 67.2 64.77 81.86 







Table S3: Comparison of Pearson’s correlation coefficients for biological replicates 
Pearson correlation coefficients for 13 samples that had been profiled twice with RNA-
Seq in our data set and in the PANCAN12 data set. 
 




TCGA-06-0125-01A-01R-1849-01 TCGA-06-0125-02A-11R-2005-01 0.89 0.88 
TCGA-06-0190-01A-01R-1849-01 TCGA-06-0190-02A-01R-2005-01 0.72 0.88 
TCGA-06-0210-01A-01R-1849-01 TCGA-06-0210-02A-01R-2005-01 0.79 0.83 
TCGA-06-0211-01B-01R-1849-01 TCGA-06-0211-02A-02R-2005-01 0.89 0.88 
TCGA-14-1034-01A-01R-1849-01 TCGA-14-1034-02B-01R-2005-01 0.75 0.78 
TCGA-19-4065-01A-01R-2005-01 TCGA-19-4065-02A-11R-2005-01 0.63 0.82 
TCGA-50-5066-01A-01R-1628-07 TCGA-50-5066-02A-11R-2090-07 0.68 0.80 
TCGA-50-5946-01A-11R-1755-07 TCGA-50-5946-02A-11R-2090-07 0.65 0.89 
TCGA-BH-A18V-01A-11R-A12D-07 TCGA-BH-A18V-06A-11R-A213-07 0.80 0.89 
TCGA-BH-A1FE-01A-11R-A13Q-07 TCGA-BH-A1FE-06A-11R-A213-07 0.69 0.65 
TCGA-E2-A15A-01A-11R-A12D-07 TCGA-E2-A15A-06A-11R-A12D-07 0.90 0.93 
TCGA-E2-A15E-01A-11R-A12D-07 TCGA-E2-A15E-06A-11R-A12D-07 0.83 0.86 






Table S4: Coefficients for HER2 signature genes  
 
This table lists the 200 HER2-signature genes, along with coefficients identified using the 
two pipelines. Among these genes, 91-92 (~46%) genes were common between the 
TCGA Level 3 pipeline and Rsubread processed (FPKM and TPM) datasets, and 188 
(94%) were common between FPKM and TPM data processed by Rsubread. 
 
 























































































































































































































































































































































































































































































































































































































































































































Table S5: Coefficients of variation for HER status predictions in TCGA breast cancer 
samples. 
HER2 status Method used Coefficient of variation 
HER2 (-) TCGA 0.62 
Rsubread FPKM 0.21 
Rsubread TPM 0.30 
HER2 (+) TCGA 0.72 
Rsubread FPKM 0.14 
Rsubread TPM 0.20 
 
CHAPTER 4 
PATHWAY-BASED DRUG RESPONSE BIOMARKER 
IN BREAST CANCER 
4.1 Introduction 
Despite advancements in molecular characterizations of cancer patients and 
availability of better treatment options, breast cancer remains challenging to treat and is 
one of the leading causes of cancer related deaths in women (1, 2). Intertumor and intra-
tumor genomic heterogeneity of breast cancer contributes to the challenges in selecting 
optimal treatments for personalized medicine (3, 4). Accurate biomarker development is 
necessary to identify breast cancer molecular phenotypes to match patients. Here, we take 
a novel approach by profiling gene expression-based pathway activity in breast cancer to 
predict response to AKT targeted therapies.  
Breast cancer is a complex molecular disease characterized by multiple genomic 
alterations. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) 
techniques are used to determine common protein alterations such as estrogen receptor 
(ER), progesterone receptor (PR), and HER2 receptor (ERBB2) status. In addition to the 
receptor status,  gene expression based “intrinsic subtypes” can be determined to guide 
therapy (5-9). While there are variations in subtyping breast cancer, the major 
transcriptional subtypes consist of luminal, ERBB2-enriched, basal-like, and claudin low 





response based on the subtypes (3, 5, 10, 11). Nonetheless, the clusters of genes defining 
the subtypes lack biological significance and there are instances that cannot beclassified 
into any specific subtypes (12). Although chemotherapies are frequently used in clinics, 
combination of chemotherapy and targeted therapy is used in some cases for improved 
outcomes (13). Unfortunately, only a fraction of the patients harboring specific 
alterations in their genomes respond to the targeted treatments (2). For example, ERBB2 
(HER2) overexpression has been effective for predicting response to HER2-targeted 
therapies such as trastuzumab (14, 15). However, one third of patients overexpressing 
HER2 do not respond or become resistant, likely due to deregulation of downstream or 
parallel pathways. Clinical trial results show that knowing the mutation status leading to 
activation of the target is insufficient to predict drug response (16). The use of subtypes 
and single gene biomarkers has improved breast cancer treatment, but oversimplifies the 
true heterogenic nature of cancer in patients and does not capture pathway-level aberrant 
signaling (15). These biomarkers also do not address the inherent interconnectedness and 
crosstalk among pathways, and alternative mechanisms of pathway deregulation. As an 
alternative, biological pathway-level aberration could be leveraged to assess drug 
response. Previous efforts have shown that the multigene-based gene expression profile 
of a pathway, a signature, is predictive of therapy response by correctly identifying 
targeted pathway deregulation linked to the therapy (17-20). However, biomarkers that 
account for pathway interactions are currently unavailable. Therefore, there is a strong 
need for the development of pathway-based biomarkers that accurately identify specific 
deregulation and account for the crosstalk among different networks to predict drug 





Cells must acquire multiple genomic alterations to grow uncontrollably and survive to 
become cancerous (1). The growth factor receptor network (GFRN) pathways play a 
critical role in cellular growth and survival in the normal cell and they are frequently 
deregulated in cancer (21).  Growth factor receptors such as EGFR, HER2, and IGF1R 
can become hyperactive due to genomic aberrations, while others are activated by protein 
modifications such as phosphorylation(21). The GFRN pathways that have been shown to 
be important in breast cancer development and survival are the HER2-PI3K-AKT 
pathway and the RAF-MEK-ERK pathway (22). Both pathways can result in subsequent 
tumor growth, proliferation, survival, and metastasis (23).When HER2 or IGF1R are 
amplified or overexpressed, PI3K mediated AKT activation leads to increased cellular 
survival by inhibiting BAD (Bcl2-Associated death promoter) (24). BAD is a pro-
apoptotic protein, and leads to apoptotic induction in normal cells (25). By inhibiting 
BAD, tumors with activated AKT escape apoptosis (24, 26). Similar to HER2/IGF1R, 
EGFR mutations or amplification leads to increased cellular proliferation, survival and 
motility via extracellular signal-related kinase (ERK) (22, 27, 28). While we currently 
have drugs that target specific aberration in these two pathways available for patient care 
or under development, complex mechanisms of pathway activation and signaling 
interactions have made effective use of these targeted drugs challenging in patients (29, 
30). 
Previously, we developed and validated ASSIGN, a novel statistical approach and 
pathway profiling toolkit that provides context-specific pathway activity estimates in 
patient samples considering the pathway crosstalk (30).  Using ASSIGN,  we generate 





accounting for the pathway interaction among the signature genes. We hypothesize that 
these signatures will provide a differential spectrum of HER2/IGF1R/AKT/BAD and 
EGFR/KRAS/RAF activity with high sensitivity and specificity in breast cancer that can 
be leveraged for drug response biomarker development. In this study, we validate our 
signature predictions in silico using breast cancer cell lines and TCGA breast cancer 
patient data by testing the ability of pathway predictors to predict a gene’s activity in 
these datasets. Next, we characterize the spectrum of pathway activity across the cancer 
cell lines and patient tumor datasets. From these analyses, we discovered a robust and 
consistent inverse relationship between the two signaling arms in breast cancer cell lines 
and in patients: HER2/IGF1R/AKT and EGFR/RAS/RAF/BAD. We show that actual 
response to drug correlates to our multipathway biomarkers with high significance. These 
results were further tested in independent lab experiments, in which we 
pharmacologically inhibited pathways of interest in an additional panel of breast cancer 
cell lines to test our predictions. To examine the importance of different types of omic 
data in prediction of drug response, we included genomic pathway-level and phenotypic 
subtypes, as well as variant and proteomic data to perform a comparative analysis of the 
models. AKT inhibitor drug response was more accurately predicted using multipathway 
activity than single pathway activity or using subtype alone. Multipathway activity 
combined with subtype information performed the best for drug response predictions. 
Finally, when multiomic data are added, for the AKT-targeted therapies, pathway activity 
based on the transcriptional pathway-level biomarker contributed the most to drug 
response predictions, but was complementary to other omic data. We modeled pathway 





multiomic biomarker to predict response to AKT targeted therapies. This biomarker has 
the potential to contribute to patient selection for AKT targeted therapies, and to provide 
personalized prediction for AKT-targeted therapy response.  
 
           4.2 Methods 
4.2.1 in vitro signature generation 
We used adenovirus to overexpress genes of interest in human primary mammary 
epithelial cell cultures (HMECs) in order to develop pathway-based gene expression 
signatures. HMECs were isolated from normal epithelial tissue taken from breast 
reduction surgeries for noncancer related reasons, and reflect normal epithelial cell 
signaling.  HMECs were grown in serum-free MEBM plus addition of a “bullet kit” 
(Lonza), and supplemented with 5mg/ml transferrin and 10-5M isoproterenol at 5% CO2. 
We used recombinant adenoviruses to overexpress AKT1, IGF1R, BAD, HER2, KRAS, 
GFP (Vector Biolabs), RAF1 (Cell Biolabs), and EGFR (Duke University) individually 
in HMECs in order to isolate the transcriptional profile reflective of each gene's 
overactive state. Recombinant adenoviruses were amplified and tittered using previously 
published protocols (31). HMECs were brought to quiescence by low serum growth 
conditions for 36 hours (0.25% MEGM, no EGF). Adenovirus (MOI 500) was added to 
HMEC conditioned media until the amplified protein from the overexpressed gene could 
be detected. Total protein levels of AKT, BAD, HER2, IGF1R, RAF, and EGFR were 
significantly overexpressed after 18 hours of virus incubation compared to control 
samples. For KRAS, 36 hours of viral incubation was necessary. Following virus 





pelleted by centrifugation, lysed for 15 minutes, and centrifuged at 13,000 x g for 15 
minutes. We validated protein overexpression and their downstream targets by standard 
Western Blotting technique (Figure 4.1). HER2, IGF1R, AKT, EGFR, BAD, RAF1, 
phospho-IGF1R, and phospho-AKT antibodies were used for protein detection (Cell 
Signaling). RNA was stored in RNAlater (Ambion), DNase treated, and extracted using 
an RNeasy kit (Qiagen). We generated RNA replicates for each overexpression status: six 
for AKT, BAD, IGF1R, and RAF1each; five for HER2; and twelve for control (GFP) 
status. Previously, we generated the EGFR signature and its corresponding control GFP 
samples with six replicates of each. Additionally, nine replicates of KRAS (G12V), 
(Q61H), and control (GFP) samples were generated. cDNA libraries were prepared from 
the extracted RNA using the Illumina Stranded TruSeq protocol and RNA-sequencing 
(RNA-Seq) using the Illumina HiSeq 2000 was performed.  
 
4.2.2. Data processing and normalization 
cDNA libraries were sequenced at Oregon Health and Sciences University using the 
Illumina HiSeq 2000 sequencing platform with six samples per lane. Single-end reads of 
101 base pairs were generated. The R package “Rsubread” was used to align and 
summarize reads to the UCSC hg19 reference genome and annotations (32, 33). EGFR 
and HER2 mRNA overexpression datasets were obtained from Gene Expression 
Omnibus via accession numbers GSE59765 and GSE62820, respectively. We processed 
and normalized HMEC signature datasets, TCGA breast cancer data (GSE62944) and 
ICBP breast cancer RNA-Seq dataset (GSE48213) using the  data processing pipeline 





AKT, BAD, IGF1R, RAF1, and RAS will soon be available on the Gene Expression 
Omnibus database. 
 
4.2.3 Single pathway optimum gene-set selection  
We generated genomic signatures, a gene-set that best describes pathway activation, 
with our HMEC RNA-Seq data and we applied these signatures to estimate the pathway 
activation status of 55 ICBP breast cancer cell lines using the ‘ASSIGN’ R package  (34). 
First, we analyzed the HMEC and ICBP data for batch effects using principle component 
analysis.  Batch effects between the two datasets were adjusted using the R package 
‘ComBat’ (35). Next, we used associated GFP control and overexpressed gene of interest 
HMEC data as training datasets for signature generation. In order to determine the 
optimal number of genes in the signature, we generated signatures with a variable number 
of genes (25, 50, 75, 100, 150, 200, 250 and 300 gene) using ASSIGN’s single pathway 
settings (36). For each signature and different gene number, we tested the predictive 
ability of the pathway estimates using (1) adaptive background alone 
(adaptive_B=TRUE, adaptive_S=FALSE) and (2) adaptive background plus adaptive 
signature features (adaptive_B=TRUE, adaptive_S=TRUE in all cases, and 
S_zeroPrior=TRUE in breast cancer cell lines only) in ASSIGN. We used default settings 
for all other parameters. The adaptive_B=TRUE parameter enables ASSIGN to adjust for 
background baseline gene expression differences between in vitro HMECs and test 
samples (i.e., cell lines), and the adaptive_S=TRUE feature enables ASSIGN to consider 
the variation in magnitude and direction of signature relevant-gene expression between in 





internal cross validations were included for further analysis. In order to validate that 
signatures accurately reflected pathway activation, we calculated pairwise Spearman 
correlation with p-value between pathway predictions and reverse phase protein array 
(RPPA) data in cell lines (34, 37). We used upstream and downstream proteins of the 
pathway of interest for the signature validations process and inconclusive RPPA data 
were excluded from the validation analysis. To determine the optimum number of genes 
for each signature, we used the p-values for each correlation. Based on the ICBP RPPA 
protein data, we found EGFR and HER2 signatures perform better with a smaller number 
of genes. Therefore, we additionally generated 5,10,15 and 20 gene signatures for EGFR 
and HER2 pathways.  For all the signatures that passed internal leave-one-out-cross-
validation, pathway estimates were included for further validation in proteomics data. A 
list of optimum gene numbers determined for each signature, the associated protein, the 
Spearman correlation and p-values used for validation are listed in Table 4.1. 
 
4.2.4. Multipathway optimal combination selection 
Using ASSIGN’s multipathway feature, optimized single pathway signatures were 
then used in various combinations with all other signatures to estimate pathway activity 
in the cell lines. In contrast to single pathway estimation where a pathway is profiled 
independently, multipathway approach considers interactions to provide a more 
biologically relevant estimation of pathway activity. Identification of multipathway 
combination that can best consider crosstalk among the signature pathways is important 
for providing the most refined pathway activity estimation (36). To determine the optimal 





pathway were correlated with RPPA protein data in the breast cancer cell lines. Pairwise 
Spearman correlations and associated p-values were used to select the most significant 
multipathway combination for rest of the analyses. 
 
4.2.5. Statistical analyses 
We used ASSIGN, a semisupervised pathway profiling toolkit for generating 
signatures and estimating pathway activity in the test samples. Details about the 
parameters used in ASSIGN generating prediction in cell lines are listed in section 4.3.2. 
To generate pathway activation estimations in TCGA breast cancer samples, we used the 
optimized signature gene list in cell lines along with the HMEC training data with 
adaptive background and adaptive signature features (adaptive_B=TRUE, 
adaptive_S=TRUE). The baseline and signature-associated gene expression can vary 
significantly between in vitro HMEC training and patient samples. Therefore, adaptive 
ASSIGN features are expected to be beneficial in this scenario by providing ‘absolute’ 
pathway activity allowing for signature refinement (36). We used Spearman rank-based 
pairwise correlation methods for pathway prediction ands protein level correlations. The 
“cor.test” function from the “stats” R package was used to calculate p-values for each 
correlation (38, 39). Student’s t-tests were performed to find the differences in pathway 
activity based on mutation status and drug sensitivity differences based on pathway 
activity. Bonferoni corrections were applied to address multiple comparisons of p-values 
for pathway activity and protein correlations. The ‘heatmap.2’ function from the 
“ggplots” R package was used for generating pathway activity and pathway activity-drug 





lines with high and low pathway (41, 42).  All analyses were conducted in R (43). 
 
4.2.6. Development of multiple regression drug 
response prediction biomarkers  
We used simple multiple regression models using predicted pathway activity in ICBP 
breast cancer cell lines to predict drug response. In order to train the models, we used the 
“MASS” R package using the ‘StepAIC’ function (44). This function selects the most 
informative variables for the dependent variable (i.e., drug response in our model) using a 
stepwise forward selection method from the list of dependent variables. First, we build 
models that only used estimated single pathway estimations or multipathway estimations 
as independent variables. Second, we used only the subtypes as independent variables. 
Finally, we used a combination of both pathway activity and subtypes together as 
independent variables. The predicted response from each model was compared to actual 
drug response to explain the variability in response by the model and reported as R2. In 
addition to pathway and subtype, we also identified the most correlated single nucleotide 
polymorphism (SNP) or insertion and deletion (indel)-containing genes and proteins from 
proteomics (RPPA) data. We built our final models and included multipathway activity, 
subtypes, SNP genes and proteins for predicting drug response and measured the R2 for 
models as we added each genomic data type into the models. The contribution from each 
type of genomics data for each drug was then measured using a residual R2 approach, 
namely by subtracting the R2 of a ‘reduced’ model from the R2 of the more inclusive 
model. For example, contribution of protein data in the multiomic model was calculated 









4.3.1. Pathway models for phenotypic characterization of  
breast cancer 
4.3.1.1. Signature generation and validation in breast  
cancer cell lines  
We used human primary mammary epithelial cell cultures (HMECs) to develop 
pathway-based gene expression signatures. In vitro signature generation method for 
HER2, IGF1R, AKT, BAD, RAF1 and KRAS is detailed in 4.2.1. Briefly, Western Blot 
analyses of these experiments demonstrating protein overexpression and pathway 
activation versus control (green fluorescent protein, GFP) are shown in Figure 4.1. 
Following expression of our gene of interest for 18-36 hours, replicates for each 
pathway’s activation state were processed for RNA, and RNA-sequencing using the 
Illumina HiSeq 2000 was performed. We processed the RNA-Seq data using methods 
described in 4.2.2. From these data, we identified those genes that best discriminate 
activation of each pathway, a pathway signature, and this signature was used as our 
pathway-level predictor. Our overall method for single and multipathway signature 
validation process is shown in Figure 4.2. 
We used the R package “ASSIGN” to generate gene-expression signatures Figure 4.3 
(A), and also for estimating single and multipathway activity in the test data (see 
Methods 4.3.2-4). Multipathway profiling approach accounts for pathways 





approach considers one pathway at a time and interactions among the pathways are not 
accounted. Therefore, our multipathway profiling approach provides a more biologically 
meaningful estimation of pathway activity for our downstream analysis (36). We 
validated our single  (Table 4.1) and multipathway (Figure 4.3(B)) gene-expression 
signatures using ICBP breast cancer cell line gene expression data and RPPA protein data  
(34, 37). For the AKT signature validation, we correlated AKT pathway predictions with 
upstream protein phospho-PDK1 (p241), PDK1, and total AKT protein levels (45). As 
expected, pathway activity levels were positively correlated with AKT signature 
predicted activity (r=0.51, p-value=0.001 for 75 gene single pathway AKT signature). 
For the BAD signature, we used the same proteins but using negative correlations since 
AKT and BAD are known to have opposing effects (46). Using this approach, we found 
the 200-gene signature to best represent the BAD pathway(r=-0.48, p-value=0.004). 
Similarly, the EGFR signature with 25 genes had the highest correlations with EGFR, 
phospho-EGFR (p1068) and a downstream protein, MEK and MAPKp. The 15-gene 
HER2 signature was optimized using HER2 and HER2 (p1248) protein levels. The 75-
gene IGF1R signature provided the highest correlation with PDK1 and phospho-PDK1 
protein levels(47, 48). We selected the 100-gene RAF1 signature based on the fact that it 
provided the best correlation with PKCalpha, PKCalpha657, MAPKp and MEK1 protein 
levels (49).  The two mutant KRAS signatures with 300 genes each were also validated 
against the phospho-EGFR protein score since EGFR activates KRAS, and the mutant 
KRAS signatures are expected to capture KRAS-activated signaling. A summary of 
single pathway activity-protein correlation is listed in Table 4.1 and multipathway 





In order to test the accuracy of the pathway-based signatures, we validated each 
signature in TCGA breast cancer data using patient sample RPPA protein data or 
mutation data (Figure 4.4). We applied our signatures to TCGA breast cancer RNA-Seq 
data (n=1082) in addition to ICBP breast cancer cell line data (of 55 breast cancer cell 
lines). For the AKT signature, we used the correlation of predicted AKT pathway with 
total AKT protein and saw a significant correlation. In addition, we correlated AKT 
pathway activity in differentiating TCGA breast cancer patient samples with PIK3CA 
mutations. As expected, AKT pathway activity was significantly higher in patients with 
the PIK3CA mutation (p-value <0.001). The opposite was expected for BAD signature 
validation. Indeed, BAD pathway activity was low in patients with the PIK3CA mutation 
(p-value <0.001). EGFR, HER2, IGF1R, and RAF pathway activities were significantly 
correlated with EGFR, HER2, IRS1 and S6 proteins, respectively (p-value <0.001)(50). 
Both the KRAS mutant signatures were able to predict high KRAS activity in patients 
with KRAS mutations (p-value: 0.01 and 0.04 for G12V and Q61H mutant KRAS 
signatures, respectively). 
 
4.3.1.2. Pathway activity in breast cancer patients 
After signature validation in cell lines and in patient tumors, we clustered pathway 
activity in 52 cell lines and 517 breast cancer samples with the intrinsic subtypes 
information available. First, our hierarchical clustering shows an intriguingly simple 
pathway activity pattern in the samples from the two datasets . This pattern is consistent 
and demonstrates that HER2, IGF1R, AKT and EGFR, KRAS, RAF, BAD  predictions 
are two distinct clusters that are anticorrelated. Figure 4.5 (A) and (B) demonstrate the 





breast cancer patient samples. Using the intrinsic subtypes, which reflect different breast 
cancer phenotypes together with ERBB2-amplification status, we demonstrate that our 
signatures show a distinct pattern of pathway activation in breast cancer cell lines that 
extends beyond any one subtype (10, 11, 51, 52),. This pathway activity pattern extends 
beyond any one subtype. For example, AKT activity is higher in ERBB2-amplified and 
luminal subtypes whereas BAD activity is higher in basal and claudin-low 
subtypes.  Also, AKT, HER2, IGF1R pathways are upregulated together, versus EGFR, 
RAS, RAF, and BAD. These findings suggest that there is a pathway level 
dichotomization of the growth factor receptor networks. In general, either 
HER2/IGF1R/AKT or EGFR/RAS/RAF pathway is on with only minimal overlap. 
Knowing this, we can hypothesize target therapy would also show dichotomous 
sensitivity pattern based on the driving pathway characterization.  
 
4.3.2. Drug response is consistent with pathway activity 
spectrum in breast cancer 
To test our pathway activity and drug sensitivity dichotomous relationships, we 
correlated the estimated pathway activity and sensitivity of 90 drug responses in ICBP 
breast cancer from Daemen et al. (2013). Drug sensitivity was defined as negative log-10 
base logarithm of 50% growth inhibitory drug molar concentration (GI50). Indeed, our 
Spearman correlation-based hierarchical clustering shows drug response correlates with 
the pathway activity patterns discussed in the results section 4.4.1.2. Specifically, 
HER2/IGF1R/AKT and EGFR/RAS/RAF/BAD show contrasting pathway activity 





with drug response in breast cancer cell lines. In general, HER2, AKT, PI3K, mTOR, and 
IGF1R inhibitors showed a strong positive correlation with HER2, IGF1R, AKT pathway 
activity indicating increased sensitivity to drug as the target pathways are activated. 
Alternatively, EGFR, MEK inhibitors, and chemotherapies show a high correlation with 
EGFR, BAD, RAF, and KRAS pathway activity suggesting higher sensitivity as this arm 
of the pathway is activated. This analysis suggests that the pathway activity is an 
important indicator of drug response and potentially important variable for building drug 
response prediction models, and that the two pathway-level phenotypes in breast cancer 
track with drug response. 
 
4.3.3. Independent validation of pathway 
activity-based drug response 
To further test our hypothesis that high pathway activity predicts drug response to 
targeted therapy specific to that pathway, we conducted a pharmacological drug 
inhibition assay using  23 breast cancer cell lines. In particular, we tested neratinib, a dual 
EGFR/HER2 inhibitor in cell lines with high HER2 and AKT activity.  Cell lines with 
high HER2 and AKT activity were significantly more sensitive to neratinib (HER2: p-
value<0.01; AKT: p-value=0.04)(Figure 4.7 (A), 4.7(B)). We also tested a commonly 
used breast cancer chemotherapeutic drug, doxorubicin, to show its efficacy in cell lines 
with high BAD, EGFR and RAF activity (Figure 4.7 (C), 4.7(D)). Cell lines with high 
BAD, EGFR and RAF activity were preferentially more sensitive to doxorubicin (p-
value=0.04, 0.03, 0.07, respectively). Additionally, we used an EGFR specific drug, 





(E), 4.7(F)). Although erlotinib was more sensitive in cell lines with high EGFR activity, 
the sensitivity difference between high and low EGFR activate cell lines was not 
statistically significant (p-value=0.15). However, significant sensitivity to erlotinib was 
observed between high and low KRAS pathway active breast cancer cell lines (p-
value=0.05). These results validated that our multipathway predictions are capable of 
predicting drug response in cell lines in an independent drug assay with additional drugs.  
 
4.3.4. Pathway models as biomarker for response 
4.3.4.1. Multipathway predictions are more predictive   
than single pathway predictions 
We used a stepwise, forward-selection, multiple regression modeling approach to 
build predictive drug response models. We hypothesize that  drug response prediction 
models will perform better than the subtypes alone for predicting response to  targeted 
therapies.  We used pathway (AKT, BAD, HER2, EGFR, KRAS (GV), KRAS(QH), and 
RAF activity) predictions only, subtype only (ERBB2-amplified, basal, luminal, claudin-
low and normal-like), and pathway plus subtype together as independent variables to 
build the models to predict sensitivity for each drug in a similar manner as described in 
section 4.3.6. For pathway predictions in the model building process, we used both single 
and multipathway predictions and contrasted the resulting R2 as outlined previously. 
Table 4.2 lists comparative analysis and additional contributions for explaining drug 
response models for AKT, PI3K, HER2/EGFR targeting, and chemotherapeutics drugs 
using single pathway predictions, multipathway predictions and multiomics data. We 





significantly better than the subtype only model, thus demonstrating the value of our 
combined pathway-subtype approach.   In general, improvement in predictive ability is 
observed with multipathway slightly and significantly when used with subtype 
data.  Figure 4.8(A) shows the variability of Sigma AKT 1/2 inhibitor response explained 
by our model in terms of R2. R2 is 0.57, 0.53 and 0.75 with multipathway predictions 
only, subtype only and multipathway plus subtypes, respectively. In multipathway 
prediction-based Sigma AKT1/2 inhibitor model, AKT, HER2 and IGF1R pathway 
predictions have been included providing slight improvement over single pathway-based 
model where only AKT and IGF1R pathways have been included. Similarly, 
improvement was seen for BIBW2992, a HER2, EGFR dual inhibitor with pathway and 
pathway with subtypes in predicting response (Figure 4.8(B)).  Although we did not have 
a PI3K signature, we were able to predict the response using upstream HER2, IGF1R and 
downstream AKT activity for GSK1059868, a PI3K-targeting drug (Figure 4.8 (C)). 
Doxorubicin’s response was also improved using the pathway activity rather than the 
subtype (Figure 4.8 (D)). For the multiomics model, we have used multipathway 
estimations of pathway activity, single nucleotide, insertion/deletion, and proteomics 
data. Overall, pathway activity-based model had the most contribution in prediction AKT 
targeted drug response (Figure 4.9). 
 
4.4 Discussion 
In this study, we characterized pathway activation status in breast cancer cell lines 
and patient data using multipathway gene-expression signatures, and generated a multi-
omic biomarker for predicting response to AKT targeted therapies. Western Blots 





RPPA protein data in both breast cancer cell lines and TCGA patient RRPA data.  These 
validated gene expression signatures were brought together to create, to the best of our 
knowledge, the first multipathway gene expression signatures. Multipathway models 
were able to predict drug response to targeted therapies in ICBP cell lines, and in an 
independent drug screen. With this approach we found intriguing inverse relationship 
between HER2/IGF1R/AKT and EGFR/KRAS/RAF/BAD pathways. We also found 
pathway activation was usually exclusive to one of the two major pathways and pathway 
activity dictates drug response. 
Using a multiple regression-based stepwise model selection approach, we have 
developed drug response biomarker for AKT therapies in breast cancer cell lines. We 
compared pathway predictions alone, subtypes alone, pathway and subtypes together, and 
with multiomics data in order to determine the best predictors of drug response. For the 
targeted therapies for which we had signatures, we demonstrated that pathway alone 
could explain significant variability in predicting drug response. Inclusion of subtypes, 
proteomics and variant data further improves the predictive power of the response 
prediction models.  
Adding additional growth factor receptor pathway nodes could increase the predictive 
power of our models. Our multipathway gene-expression signatures could also be used to 
interrogate other cancers, and measure pathway activity with ASSIGN’s adaptive 
features. However, pathway contributions in predicting drug response may vary across 
cancer types. Therefore, pathway predictions may need to be revalidated in each cancer 
type for better reliability before drawing conclusions. Multiple regression models using a 





but this approach has many limitations. An important assumption in the model selection 
method is that all included independent variables are relevant, and that no colinearity 
exists among these variables. In biology, there are redundancies in pathway regulations 
and activities. Therefore, our included pathways may show colinearity and falsely 
increase the predictive power of the model. For the AKT inhibitors modeled in this study, 
we may have missed other relevant pathways, important rare variants, protein changes 
that could have impacted the response. In the future, we plan to include more growth 
factor receptor pathway nodes for improved refinement of the signaling pathway 
characterization. We will improve our models for response prediction by accounting for 
interaction in mRNA, proteomics, variant and methylation data to lower the risk of over-
fitting. We will also test our response models in patient cells in vitro. Overall, our newly 
generated multipathway/mutliomic characterization for pathways could be helpful in 
selecting the appropriate patients for clinical trial designs to test response and efficacy of 
the targeted therapies. These pathway-based models are useful for drug response 
biomarker development, and for implementing personalized medicine. Pathway-based 
multiomic drug response models, however, need to be validated in prospective clinical 










Table 4. 1: Spearman’s correlation between pathway activity and proteomics data 






AKT 75 AKT 0.51 0.002 
BAD 200 AKT -0.48 0.004 
EGFR 25 EGFR 0.41 0.02 
HER2 15 HER2 0.62 <0.001 
IGF1R 75 PDK1 0.53 0.001 
KRAS 
(G12V) 
300 EGFR 0.46 0.01 
KRAS(Q61H) 300 EGFR 0.45 0.01 
































Subtype only: 0.53 
pathway + subtypes: 
0.75 
pathway + subtype + 
protein + snps/indels: 
0.82 











Subtype only: 0.25 
pathway + subtypes: 
0.43 
pathway + subtype + 
protein + snps/indels: 
0.82 










Subtype only: 0.17 
pathway + subtypes: 
0.90 
pathway + subtype + 
protein + snps/indels: 
0.77 












Subtype only: 0.13 
pathway + subtypes: 
0.51 
pathway + subtype + 
protein + snps/indels: 
0.80 








Table 4.2 (continued) 
Drugs 


















Subtype only: 0.36 
pathway + 
subtypes: 0.38 
pathway + subtype + 
protein+ snps/indels: 
0.70 
pathway + subtype+ 
protein: 0.61 
Doxorubicin 







Subtype only: 0.15 
pathway + 
subtypes: 0.36 
pathway + subtype+ 
protein+ snps/indels: 
0.55 










Subtype only: 0.18 
pathway + 
subtypes: 0.53 
pathway +subtype + 
protein+ snps/indels: 
0.70 










Figure 4. 1: Western blot protein overexpression validation. (A) IGF1R, (B) HER2 
(ERBB2), (C) KRAS, (D) BAD, and (E) RAF1 signatures generated in human mammary 










Figure 4. 2: Signature generation and validation. We overexpressed gene of interest in 
human mammary epithelial cells using Adenovirus.  Signature HMEC data and all test 
data are processed and normalized using the same pipeline. Then ASSIGN was used to 
generate single and multipathway signatures and these signatures were used in test 
datasets such as ICBP breast cancer cell lines and TCGA breast cancer patients. 
Estimated pathway activities from ASSIGN were validated against proteomics and 
mutation data for the test samples. 
B Signatures,


























































































































Figure 4. 3: Gene expression signatures and validation in ICBP43 dataset. (A) 9 gene 
expression signatures are shown with variable number of genes. (B) Signature predictions 
using RNA-Seq data were validated in the reverse phase protein array (RPPA) data in 
breast cancer cell line data from Daemen et al. (2013). 75 gene AKT, 200 gene BAD, 25 
gene EGFR, 250 gene ERK, 15 gene HER2, 75 gene IGF1R, 300 gene KRAS-GV, 300 
gene KRAS-QH, 100 gene RAF signatures were validated with total AKT, total AKT, 
phospho-EGFR, phospho-PKCalpha, phosphoHER2, total PDK1, phospho-EGFR, 
phospho-EGFR and phospho-MAPK, respectively. Scatter plots and Spearman’s 















Figure 4. 4:  Pathway prediction validation in TCGA BRCA dataset. AKT, BAD, EGFR, 
HER2, IGF1R, RAF, KRAS (G12V) and KRAS (Q61H) signature validations in TCGA 
breast cancer patient samples. Mutation data from 417 patients and RPPA protein data 













Figure 4. 5: Analysis of pathway activity and intrinsic subtypes. (A) 52 breast cancer cell 
lines and (B) 517 breast cancer patient samples show a similar pathway-activity 

























Figure 4. 6: Correlation heatmap of Pathway-drug response .Pathway-drug response 
correlation demonstrates pathway specific drug response in 52 breast cancer cell lines and 















Figure 4. 7: Pathway dichotomy validation in an independent drug assay. Cell lines with 
high  AKT (A), and HER2 (B)  activity are significantly more sensitive  to neratinib (p-
value=0.04, p-value<0.001, respectively);  BAD (C) and EGFR (D)  activity are 
significantly more sensitive to doxorubicin (p-value=0.04, 0.03, 0.07, respectively); 
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Figure 4. 8: Predicted versus actual drug responses. Variability explained by the stepwise 
multiple regression models is shown for (A) Sigma AKT 1/2 inhibitor (B) BIBW2992 
(C) GSK1059868 (D) doxorubicin for pathways only, subtypes only and pathways with 
subtype models.  For all cases, pathways only models were better than the subtypes alone 
models and pathways with subtype models were the best.  
A.          B.  
  








Figure 4. 9:  Performance of the multiomic drug response model. Multiomic model 
explained R2 for drug response across all 90 drugs using 52 breast cancer cell lines 
ordered by pathway contribution. The pathway-based models (red bars) explain the 
variability in the drug response for the most drugs. 
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TRANSCRIPTOMICS DATA INTEGRATION WITH ELECTRONIC 
HEALTH RECORD USING OPENEHR 
5.1 Introduction 
The healthcare industry has become profoundly information intensive. In this 
information era, healthcare professionals cannot afford manual information processing. 
Further, the current amount of data needed for effective patient care already exceeds 
human cognitive capacity (1, 2). The recent emphasis on precision healthcare will lead to 
an increase in the size and scope of the information available for decisions (3, 4). Thus, a 
systematic approach to information management and integration is needed for efficient 
and effective clinical care (5).  Gene expression data pose additional challenges for 
human comprehension at the point of care. Effective genomic data sharing and 
integration with electronic health record (EHR) systems is key for the adoption of 
genomics data in routine clinical care and secondary use (6). The perceived value of 
genomic information at the point of care is highlighted by the adoption of active clinical 
decision support for pharmacogenomics by several oncologic and academic medical 
centers (7).   
Transcriptomics data, also known as gene expression profiling data, are cellular 





happening in a cell at a specific time as a consequence of various genetic variants as well 
as environmental and disease-specific molecular alterations. Thus, unlike DNA-level 
variant information, which mostly remains unchanged over a lifetime, transcriptomics 
data provide time-dependent, disease-specific surveillance and predictive insights.  
Transcriptomics data offer many opportunities to improve clinical care by providing 
insights about disease phenotypes, prognosis, and drug sensitivity at the time of 
assessment (8-14). Currently, gene-expression-based assays such as OncotypeDX, 
MammaPrint, Rotterdam signature, and PAM50 are being used in clinical decision-
making (15-18). These tests are usually outsourced to Clinical Laboratory Improvement 
Amendments (CLIA)-certified laboratories, and the actionable results are sent back to 
clinicians as narrative reports in static formats such as portable document format (PDF), 
fax, or mail. Although these reports are often uploaded to EHR systems, they are not 
available in a computable format that could be readily used in applications such as 
Clinical Decision Support (CDS) systems (19). 
Despite the clinical use of transcriptomics-based biomarkers in clinical care and in 
clinical trials, to our knowledge no study has investigated the feasibility of addressing 
this clinical information need with a computable and sharable format compatible with 
EHR systems. To guide clinicians with genomics data with CDS, data are required to be 
represented in computable format and accessible to CDS (20-24). In addition, these data 
must be interoperable to provide continuity of care, disease surveillance, and secondary 
use, such as in research. Here we propose a platform-independent data model for a 
computable and interoperable representation of transcriptomics data. We demonstrate the 





propose an architecture for the flow of transcriptomics data to addresses some of the key 
challenges of integrating genomics data within EHR. Our goal in this study is not to 
implement the transcriptomics data instances in the current EHRs yet. Our goal here is to 
assess the current feasibility to create instances of gene expression data, not gene-variant 
data or genetic testing data, leveraging and adapting available standards and open-source 
resources plausible for integrating and sharing such data across EHRs in a platform-
independent manner.  
 
5.2 Background 
Access to next-generation sequencing together with available genomic-targeted 
therapeutics is particularly interesting for selecting patients for relevant clinical trials and 
has been shown to be feasible in recent studies (25). There are already drugs available or 
under development in clinical trials to target some of the genomic abnormalities. 
Heterogeneity of diseases such as cancers has made patient selection extremely 
challenging for appropriate therapeutic intervention when the genomic feature is not very 
common (26). Integrated genomic data with the EHR not only can help with patient 
selection for appropriate therapeutic intervention or clinical trial recruitment, but also 
enlighten us further on possible mechanisms of response and hypothesis generation.  
Studies have explored how genome sequence variant data could be integrated for 
CDS computations (20, 27-30). In general, the challenges to integrating genomics data in 
the EHR include inadequate standardized laboratory reporting methods; the relatively 
high cost of sequencing; and the lack of a standard data representation format, physician 





genomics testing (19). Transcriptomics data are more complex than the much more 
studied gene-variant data because (1) our understanding of transcriptomics data is rapidly 
evolving and the interpretation of knowledge changes more frequently than the gene-
variant data; (2) transcriptomics data are numbers that must be computable for CDS use 
unlike the categorical variant data; (3) no reference value has been established for normal 
expression for each gene. Usually, the data are compared to a set of reference gene 
expression levels established as a biomarker in clinics or a potential biomarker in a 
clinical trial setting. In addition, the unit of measure can vary with the analysis pipeline. 
Therefore, there is a need for investigating the feasibility of representing computable 
transcriptomics data, specifically with emerging electronic healthcare data standards.  
 
5.2.1 Previous efforts to integrate genomics information 
The display of genetic information influences a clinician’s ability to use that 
information appropriately (31). The National Institutes of Health (NIH) have sponsored 
initiatives such as Clinical Sequencing Exploratory Research (CSER) and the electronic 
Medical Records and Genomics (eMERGE) network with a vision of incorporating 
genomic information in routine clinical care.  The CSER consortia explore the storage 
and display of genomics data in the EHR, and the eMERGE network focuses on 
implementing pharmacogenetics and other genetic medicine initiatives using the EHR. 
Since 2007, the eMERGE network has made significant advancements in integrating 
genetic test results and clinically important variants in the EHR. However, these genetic 
test results are often not computable as required in applications such as CDS, which are 





collaborative studies across the CSER and eMERGE sites have shown that genetic 
information has many overlapping clinical use-case scenarios and have stressed the 
importance of developing an effective decision support knowledge-base and CDS for 
genetic results to recommend appropriate actions for medically actionable genetic 
information (32). Despite the support, genetic information is displayed as PDFs or as 
paragraphs of texts in more than 50% of the sites, and none of the sites currently have 
automated mechanisms of capturing disease-defining genetic information in the EHR. 
The same study also identified the need to link genetic information of genetic knowledge-
base that place the genetic information in an appropriate context in the EHRs. The 
integration of genomic data linked with phenotype data is not only necessary to 
implement current medical-genomics knowledge but also imperative for syncing with the 
evolving genomic knowledge-base, discovery of new genomics knowledge, and 
validation of knowledge in large sample sizes and diverse populations (34). Nevertheless, 
a survey of informatics approaches to whole-exome and whole-genome clinical reporting 
in the EHR shows that six eMERGE sites use PDF documents for genetics diagnostic 
reporting and interpretation (34). For genomic medicine to be successful, discrete and 
computable genomic data are required in the EHR (35). Raw genetic data are not feasible 
to store in the EHR because of the large volume of the data and the lack of clinical 
meaning without further processing (36). Although raw unprocessed data are not feasible 
to store in the EHR, the EHR should have the capability to store and display post-
processed genomics information in a computable manner appropriate for clinical decision 
support (20, 30, 32).  In addition, the required minimal functionalities specified by 





phenotype-genotype relationship; (3) whenever possible, EHR systems with decision 
rules using the discrete data to trigger CDS recommendations and assessments; and (4) 
EHR systems able to retrieve external provider reference and patient education content 
(37). These are considered to be the ‘minimal functional requirements’ for basic genomic 
data integration; yet, no EHR has met these required functionalities (37).  
 
5.2.2 Data modeling approaches, standards, and terminologies 
Various international organizations have dedicated their efforts to developing 
standards, terminologies, and clinical models for interoperability and implementation. 
Health Level Seven International (HL7), a standards developing organization, is 
dedicated to providing a comprehensive framework and standards for interoperable 
electronic health information (37-40). HL7 standards provide comprehensive framework 
to exchange, integrate, share, and retrieval of electronic health information. HL7’s 
Version 2 (V2) messaging standards are the most widely implemented standards for data 
exchange for healthcare in the world. HL7 Version 2 includes messaging for laboratory 
test results, which use LOINC codes as the “question” for a laboratory test and other 
standards such as SNOMED CT codes as the “answer.” The clinical genomics group in 
HL7 has developed specifications to support personalized genetic-based medicine. This 
group focuses on providing structure for clinical decision support, translational medicine, 
and research. HL7 Version 3 (V3) Clinical Document Architecture (CDA) provides a 
document markup standard that specifies the structure and semantics of clinical 
documents for data exchange. Fast Healthcare Interoperability Resources (FHIR) is a 





focusing on implementation. FHIR uses “resources” or modular components that can 
easily be aggregated into working systems to solve real world implementation problems.  
Clinical models are represented as archetypes or templates. Archetypes provide a 
semantic collection of required data that describes a certain concept (e.g., blood pressure) 
whereas templates specify or aggregate related archetypes that serve a certain purpose 
(e.g., progress note). Such reusable templates and archetypes facilitate development of 
new clinical models by eliminating the need for the substantial effort of de novo data 
modeling. The openEHR Foundation provides highly reusable and modular archetypes 
that can be reused with different templates in various operational forms (41, 42). The 
produced templates can be rendered in operational forms such as XSD schemas and 
JSON format to enable implementation within clinical information processes including 
CDS (43-47). openEHR archetypes are shared with the informatics community through 
the Clinical Knowledge Manager (CKM) repository. The Clinical Information Modeling 
Initiative (CIMI), another international consortium, is dedicated to providing a common 
representation of health information to assure semantic interoperability across the 
evolution of standards representing clinical information (48).  
Specifically for genomics data, the HUGO Gene Nomenclature Committee (HGNC) 
is the only international authority that approves standardized nomenclature for human 
genes as symbols and identifiers (IDs) (49).  Whereas HCNC is an international effort, 
ENSEMBL and ENTREZ are prominent regional initiatives for providing gene IDs, and 
they are also used widely in the bioinformatics field. Additionally, Web services based on 
Representational State Transfer (REST), supported by HGNC and ENSEMBL databases, 





leveraged to create scalable and up-to-date “gene” elements. The HL7 V2 
Implementation Guide for clinical genomics has used HGNC gene symbols for reporting 
DNA sequence variants located within a gene (50). In the future, it may be possible to use 
various FHIR resources to enable the exchange of gene expression data with EHR 
systems.   
 
5.3 Methods 
5.3.1. Model design process 
The model was designed using a five-step process that culminated in the application 
of the model to breast cancer gene expression data. First, we studied publicly available 
transcriptomics data from databases, research articles, and laboratory report formats. We 
identified the required elements for describing the patient, diagnoses, sample, and 
transcriptomics data. Second, we designed an initial model including all required 
elements from the previous step.  Third, we validated a small dataset containing two 
genes and identified additional data features present in gene expression data such as units 
and gene identifiers. Fourth, we identified the available standard data element models and 
terminologies that could be used to express our transcriptomics data model. Finally, we 
demonstrated the application of the resulting model with transcriptomics data and 
associated metadata from a breast cancer patient.  
 
5.3.2. Modeling artifacts 
In this study, XSD language was used to define a schema for the proposed 





Markup Language (XML). Both XSD and XML provide platform-independent and 
operational forms of data, as well as the bases for scalable publishing of data models and 
instances (51). oXygen XML Editor 16.1 was used for generating the XSD and XML 
instance files (52). Another template of the report was formulated according to the 
openEHR Clinical Models approach and using openEHR archetypes and template 
modeling tools (53).  
 
5.3.3. Description of the data sample 
We used publicly available breast cancer sample RNA-Sequence data from The 
Cancer Genome Atlas (TCGA) as an example representation of the gene expression data 
with our XSD model.  The specific sample (TCGA-A2-A0CX-01A-21R-A00Z-07) was 
accessed on March 3, 2015 (54). This sample was sequenced by Illumina HiSeq 2000 
sequencer and processed by UNC RNA-Sequence Version 2 protocol. We used the 
“Level 3” RNA-Seq Version 2 data file “unc.edu.b1ecc303-eb55-436f-9629-
cdac63bde297.1171987.rsem.genes.normalized_results” for our example representation. 




5.4.1. Gene expression model 
The assumption behind the proposed model is that the model represents RNA-Seq 
gene expression results for a specific patient using a specific sample performed on a 





Reporting of a variable number of genes and multiple analysis tools in the specific 
analysis pipeline are accommodated. The data elements in the proposed model are shown 
in Figure 4.1. In this XSD model, we have patient-, clinician-, document-, and author-
specific elements to describe the individuals involved. These elements are required in the 
model. We have provided two optional elements for specifying reason for testing and 
diagnosis. Sample specific information such as node status and tumor size is represented 
within the “sample” element. The transcriptomics data processing pipeline and the 
processed data are represented in the “test” element.  
We used available archetypes from openEHR Clinical Knowledge Manager (CKM) 
to serve as fundamental components such as “Result Report” and “Laboratory Test” 
compositions, and the “Individual’s personal demographics” cluster (47). In addition, a 
new archetype was extended from available OBSERVATION subtype, specifically, from 
openEHR-EHR-OBSERVATION.lab_test.v1openEHR-EHR-OBSERVATION.gelab.v1 
cluster to meet specific requirements for reporting gene expression lab results. The 
template produced was exported to operational form as Template Data Schema file in 
XSD format. To represent gene names, we used the HGNC standardized nomenclature 
that is already in use in the HL7 Version 2 genetic variation reports (55). In addition, we 
mapped our model elements to available HL7 V2 and V3 standards, openEHR archetypes 
and templates, and CIMI model instances. Unfortunately, data modeling editors required 
for developing CIMI models are not yet published. Therefore, development of custom 
models with available CIMI models was not feasible.  
A complete list of elements of our model mapped to openEHR, HL7 and CIMI is 





“test” element. The “test” element is one of the unique data elements for which no 
standard data elements have been established. Hence, we developed an “Extended Gene 
Expression Test Specifications” archetype that is equivalent to our XSD model’s “test” 
element. The detail of the “Extended Gene Expression Test Specifications” archetypes is 
shown in Figure 5.2. Computable versions of the model and its detailed description can 
be found at https://github.com/mumtahena/Transcriptomics_data_model. 
 
5.4.2. Implementation architecture and process 
Figure 5.3 shows how the model can be used in the flow of transcriptomics data 
instances within the healthcare system. When a CLIA-certified laboratory performs a 
gene-expression-based assay, raw data and associated pipeline information are stored in-
house. The laboratory uses the transcriptomics data knowledgebase with reference 
genome data and annotation resources as represented by “1” in Figure 5.3 to process the 
raw data using the established analysis pipeline. The CDS algorithms can use the same 
knowledgebase to compute the transcriptomics data. We assume that the laboratory and 
the knowledgebase will have computable “reference biomarker” transcriptomics data 
available using our model or a model similar to ours.  The laboratory then delivers the 
transcriptomics data results to the EHR in a machine-readable format using the proposed 
data model along with a traditional narrative summary of the result interpretation (“2”). 
Instances contain patient-, platform-, and analysis-pipeline-specific information, and the 
expressions at the individual gene levels for a variable number of genes.  
A single data instance is all that is required to store one or more genes with 





descriptions from one test. These normalized gene expression values are computable, and 
can be shared, and theoretically used in CDS.  CDS services then use the computable 
patient-specific data from the EHR and a knowledgebase to generate patient-specific 
recommendations, as shown by “3.”  These recommendations are delivered to clinicians 
by the EHR during routine patient care at the point of care (“4”). With the advent of new 
technology, analysis pipelines, and new CDS algorithms and knowledge, the data stored 
using our proposed model, transcriptomics data, can be reevaluated and a new 
interpretation of the data can be generated. Further, advanced CDS systems will be able 
to use the computable gene expression values from all genes or a subset of the genes to 
provide assessments and recommendations, trigger recruitment alerts for clinical trials, 
develop new potential biomarkers, or assess the validity of current biomarkers with the 
linked phenotype information from the EHR.  Thus, the computable representation by our 
model of transcriptomics data accommodates patient-focused and population-based 
decision-making use cases. 
 
5.5 Discussion  
We took a practical approach to possible integration of transcriptomics data into the 
EHR considering the current challenges and future evolution of bioinformatics 
knowledge, EHR capabilities, CDS modules, and laboratory processes. In this study, we 
proposed platform-agnostic transcription data models to provide an interoperable and 
computable representation of such data. We emphasized that our goal was to study if we 
could represent transcriptomics data using currently available open-source resources such 





integrating transcriptomics data in routine clinical care.  
We incorporated open-source, widely used, platform-independent, and easy-to-use 
resources to build and validate our model with patient data.  To our knowledge, this is the 
first study to investigate the feasibility transcriptomics or gene expression data 
integration into EHRs. The transcriptomics field is rapidly evolving, and it is expected 
that standard terminology systems will lag behind medical knowledge (56). Although 
openEHR is rich in archetypes and templates, we were unable to map elements specific to 
gene-expression to currently available openEHR templates or archetypes. Moreover, 
CIMI is an excellent effort in standardizing data models, yet the tools needed for edit and 
development are  not yet published.  This study identifies the gap between the required 
data elements for transcriptomics data and available openEHR archetypes to represent the 
data. Furthermore, we provide a preliminary custom-made transcriptomics data archetype 
extended from openEHR archetype to accommodate the specific requirements of 
transcriptomics data. The computable models are available at 
https://github.com/mumtahena/Transcriptomics_data_model. We plan to update and 
validate our model as more archetypes, standards, terminologies, and data models 
become available. 
A limitation of our study is that we demonstrated this model using only one patient’s 
RNA-Seq-based gene expression data. In the future, we plan to extend our example 
validations with data from other sequencing platforms such as microarray, qPCR and 
NanoString. Although there may be situations where two samples from the same patient 
are compared, the scope of this study was limited to assessing whether processed 





efforts. Further, while gene-level summarized qPCR, nanostring data are very similar to 
the RNA-Seq and microarray gene-level summarized data we used for demonstration, our 
future efforts will focus on integrating transcriptomics data from other platforms and 
including multiple samples from the same patient for differentially expressed gene 
analysis. In addition, we would like to develop and demonstrate CDS prototypes that can 
apply CDS algorithms on the data instances produced by the model. We also plan to 
improve this data model based on the specifications of the future HL7 Clinical Genomics 
specifications and CIMI as they become available and validate it with the implementation 
with available FHIR resources.  
 
5.6 Conclusion 
 To address the challenges of incorporating transcriptomics data in routine clinical 
care and in research, we developed an EHR platform-independent model representing 
transcriptomics data, built in part on openEHR general data element archetypes and 
standard terminologies. The resulting model lays the groundwork necessary for future 
research and development in this area.  
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Figure 5.1: Overview of the elements of the XML Schema Definition (XSD) 
transcriptomics data model. Dark grey lines represent required elements and light gray 









Figure 5.2: The custom-made ‘Extended Gene Expression Specifications” archetype in the 
transcriptomics data model using openEHR archetype and templates. Gray color text represents 
zero occurrence items. Details about optional, required, and zero occurrence items can be found in 













Figure 5.3: Integration of transcriptomics data instances with electronic health record (EHR) 
systems showing various steps denoted in numbers (1-4). The dotted lines show information flow 
to and/or from transcriptomics data instances. “1” shows the information flow using reference 
biomarker data instance represented using the proposed model. “2” denotes the information flow 
from the laboratory to the EHR in a machine-readable format using the proposed data model 
along with a traditional narrative summary of the result interpretation. CDS services then use the 
computable patient-specific data from the EHR and a knowledge base to generate patient-specific 
recommendations, as depicted by “3.”  “4” shows that these recommendations can be delivered to 
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CHAPTER 6 
DISCUSSION 
This dissertation focuses on pathway-based drug response biomarker development in 
breast cancer and assesses the availability of open-source resources for integrating gene 
expression data in the patient electronic health record (EHR). A summary of findings, 
significance, limitations, and future directions for this dissertation work is presented 
below. 
6.1 Summary of findings 
Gene expression profiling has identified five molecular subtypes of breast cancers. 
Breast cancer patients are known to have different prognosis, survival and drug response 
based on the subtypes (1-4). Gene expression-based pathway biomarkers have previously 
been shown to be effective in predicting drug response in patients by correctly identifying 
targeted pathway deregulation (5-8). Inherent interconnectedness of signaling pathways, 
however, makes accurate estimation of pathway activity challenging. Therefore, first, in 
collaboration with the Johnson lab, I developed ASSIGN, a pathway profiling toolkit that 
accounts for interactions among pathway nodes, background base-line gene expression 
variation in various cellular contexts. I validated ASSIGN in cell
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lines as well as with patient data to test the accuracy of pathway activation estimates. 
Chapter 2 is the published manuscript describing and validating ASSIGN. Next, I wanted 
to build in silico genomic pathway signatures of overexpressed genes of interest to assess 
pathway activity in heterogenic samples(9).  Bild lab colleagues used human primary 
epithelial cell cultures (HMECs) to overexpress ERBB2 (HER2), IGF1R, AKT, BAD, 
RAF1, EGFR and KRAS genes with adenovirus. To minimize the variation due to the 
data analysis and normalization pipeline, I reprocessed RNA-Sequencing dataset for all 
of the gene-overexpressed HMEC samples, 55 breast cancer cell lines and more than 
10,000 patient samples across 24 cancer types from The Cancer Genome Atlas (TCGA) 
in collaboration with Dr. Stephen Piccolo.  This dataset is currently publicly available on 
the Gene Expression Omnibus via accession GSE62944. This consistent data processing 
is important in filtering out technical artifacts that may have been present in the data 
otherwise. I validated this alternatively processed TCGA dataset and showed this dataset 
performs better in downstream analyses than the TCGA- processed RNA-Sequencing 
dataset. Chapter 3 is the accepted manuscript describing the alternative data processing 
and the validation of the compiled dataset. Then, I used ASSIGN to generate genomic 
signatures and to estimate pathway activity in samples. I validated pathway estimates of 
55 breast cancer cell lines and in 1082 TCGA breast cancer samples in silico. Using the 
validated signature-based pathway activity, I characterized two major aberrant signaling 
pathways in breast cancer: HER2/IGF1R/PI3K/AKT/BAD and EGFR/RAS/RAF/MEK 
pathways in cell lines and in patient samples. My analyses show that the pathway activity 
demonstrates a consistent spectrum that spans across breast cancer subtypes. This result 
suggests that using receptor status and/or subtypes for characterizing breast cancer 
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oversimplifies the true complexity of growth factor signaling networks in breast cancer. I 
show that there is an inverse correlation between these HER2/IGF1R/PI3K/AKT/BAD 
and EGFR/RAS/RAF/MEK pathways. Specifically, high HER2, IGF1R, AKT activity is 
associated with low BAD, EGFR, RAS and RAF activity and vice versa. The pathway 
characterizations follow a drug response pattern that is consistent with the pathway-
signaling pattern. HER2, PI3K, AKT high activity is associated with high sensitivity to 
drugs that target these pathways but are resistant to chemotherapeutics and EGFR, MEK 
targeting drugs. In an independent drug assay, the pharmacologic inhibition of AKT, 
HER2/EGFR, EGFR pathways further validated the pathway predictions in 
differentiating drug sensitivity based on pathway activation. Then, I used the pathway 
predictions and drug response in breast cancer cell lines to build drug-specific response 
models. I used a stepwise model selection method for the optimum response model where 
the dependent variable is the drug sensitivity data in cell lines, and independent variables 
are the pathway estimations (AKT, BAD, HER2, EGFR, KRAS(GV), KRAS(QH), and 
RAF activity) or the subtypes (ERBB2-amplfied, basal, luminal, claudin-low and normal-
like) or both the pathway estimation and subtypes.  I found that pathway estimations 
contribute more in the drug response prediction models than the subtypes.  However, 
multipathway predictions and subtypes together make better models than pathway-only 
drug response models. Finally, I incorporated multiomics data, specifically, single 
nucleotide polymorphism, insertions/deletions, and RPPA protein data to build the 
models. In the multiomics models, pathway activity contributed the most for the targeted 






Next, I assessed the feasibility of integrating gene expression data with currently 
available data standards, terminology and archetypes for future applications of gene 
expression-based biomarkers in the EHR for routine clinical care. After identifying the 
key features of the gene expression data, I proposed a preliminary data model in 
extensible markup language schema (XSD) that can represent the transcriptomics data in 
a platform- independent manner. Then, I tried to map each of the data elements to 
publicly available data models/initiatives/archetype clusters. The feasibility of mapping 
the preliminary data models to clinical information modeling initiative (CIMI) 
interoperable models was studied. Due to the unavailability of existing data models that 
could represent transcriptomics data and a published editor for making a custom model, 
the proposed preliminary model could not be mapped to CIMI models. Then, I tried 
mapping data elements to openEHR archetypes to represent transcriptomics data. I could 
map the generic data elements such as patient-, sample-, clinician-, and diagnosis-data 
models with available archetypes. However, no archetype or cluster was available from 
openEHR that could accurately represent specific transcriptomics data. Therefore, I 
extended one of the flexible laboratory report clusters (openEHR-EHR-
OBSERVATION.lab_test.v1openEHR-EHR-OBSERVATION.gelab.v1) to 
accommodate transcriptomics data. Then, I used this archetype to represent a publicly 
available patient sample. Chapter 5 describes the preliminary models for the development 
methods, high-level design validation using openEHR archetype and a proposed 
architecture to show how transcriptomics data information could flow within the patient 







The goals of personalized medicine remain elusive due to challenges in matching 
specific genomic aberration in an individual to his drug response. Traditionally, we 
carefully study genomic aberrations in controlled environment to link drug response. 
However, it is inherently challenging to apply our knowledge at the bench about the 
genomic aberration and drug characteristics in patients. Therefore, the goal of this 
dissertation is to take data produced at the bench, apply it to control datasets to develop 
the biomarker and finally, to study the feasibility of implementation of such biomarker in 
electronic health record so that the gene-expression-based biomarkers can be 
implemented in patient care. Specifically, development of pathway and drug response 
biomarkers falls into the translational biomedical informatics domain and assessment of 
feasibility of integrating gene expression data falls into the clinical informatics domain. 
Below is the specific significance of my work for this dissertation. 
Although pathway profiling can be informative in assessing signaling aberration, a 
traditional single pathway approach falls short in being specific in assessing signal when 
there is interaction of gene in various pathways in vivo. ASSIGN, a novel context-
specific pathway profiling toolkit, can be used to estimate the level of pathway aberration 
in a specific patient tumor accounting for tumor-specific gene expression differences and 
pathway interaction. Thus, ASSIGN can contribute implementing personalized genomics-
based medicine by identifying pathway aberration with high sensitivity and specificity.  
The Cancer Genome Atlas (TCGA) is a wonderful source of patient tumor and 
clinical data and is widely used in cancer research. RNA-Seq data from this resource has 





pipeline for data processing and old gene annotation files, and the alignment of the read 
maps are less accurate than currently available new aligners. Therefore, we reprocessed 
the TCGA RNA-Seq dataset with an alternative pipeline and showed that our dataset 
produces a more consistent downstream data analysis than the TCGA RNA-Seq dataset 
from same samples. The reprocessed TCGA RNA-Seq dataset is the largest to date, 
including more than 10,000 tumor and normal patient samples. Additionally, patient 
identifications in clinical data and RNA-Sequencing data were matched for easy 
downstream analyses. This dataset can be accessed on the Gene Expression Omnibus via 
accession number GSE62944. This is a significant effort since it takes thousands of hours 
of computing resources to generate such a dataset. Researchers now have an alternate 
version of widely used TCGA patient mRNA dataset that they can use for potentially 
improved analysis results. 
AKT, BAD, HER2, EGFR, IGF1R, RAF, KRAS (G12V) and KRAS (Q61H) mutant 
signatures generated in human mammary epithelial cells are validated in cancer cell lines 
and in breast cancer patients. These signatures are potentially applicable to other 
signaling pathway associated including other types of cancer, immunological, and 
neurological diseases. The proposed biomarkers for AKT inhibitors could provide better 
patient selection strategy in clinics after validation in clinical trials.  
The proposed data model for representing transcriptional data is preliminary but a 
necessary first step towards implementing computable, discrete, sharable genomics data. 
If genomics data could be represented in this way, employing clinical decision support 
rules on such data is theoretically possible. Thus, it would be feasible to provide decision 





genomics data.  
 
6.3 Limitations 
      Although ASSIGN considers background gene expression differences between 
training and test samples, ASSIGN cannot capture patient-specific background variation. 
Signature adaptive feature may sometimes infer to other biological context if the signal in 
the test data is not strong. Therefore, careful validation of the ASSIGN’s adaptive 
predictions is needed. 
The alternatively processed RNA-Seq dataset from TCGA does not provide transcript 
or gene level expression unlike TCGA provided RNA-Sequencing data.  This dataset is 
normalized using a ‘single-sample’ normalization method to avoid change in expression 
values with the addition of new samples to the dataset. Therefore, it may still be 
necessary to correct for intersample variation when comparing data across different 
cancer types.  
Addition of other relevant growth factor receptor network may further refine pathway 
estimates and can better differentiate between targeted pathways. Developed biomarkers 
for AKT inhibitors are potentially overfitted from mulitomics data and model R2’s are 
likely higher than their actual performance. Therefore, more rigorous validation of the 
biomarkers is necessary prior to testing the biomarkers in clinical trials. 
The transcriptomics data model currently can represent RNA-Sequencing normalized 
data. However, transcriptomics data from other platforms are not tested and expert 
validation of the data model is necessary to further refine and improve the model to 





6.4 Future directions  
Gene expression-based pathway estimation leading to patient-specific drug response 
biomarker development and possible integration of gene expression data in the EHR are 
the two main focuses of this dissertation work. I developed ASSIGN for context specific 
pathway activity estimation. In the future, I want to accommodate multiomics data in 
ASSIGN to build robust multiomic- based drug response prediction models to minimize 
overfitting of multiomic data. This way we can consider DNA-, RNA-, proteomics-and 
methylation-level data interaction at once in determining drug response with more 
sensitivity and specificity. In the future, the compendium of mRNA data will be updated 
as more patient samples are publicly available for publication and to share. I generated in 
silico genomic signatures of AKT, BAD, HER2, EGFR, IGF1R, RAF, KRAS (G12V) 
and KRAS (Q61H) genes that are important in growth factor receptor signaling 
pathways. Arguably, the same gene expression signatures may be used in other cancer 
types to identify and target deregulation. However, validation of signature predictions is 
required for generalizability.  These signatures can be applied to other cancer types for 
measuring pathway activity after additional cancer type-specific validation with either 
protein or mutation data. I would like to apply these signatures to other cancer types and 
explore the possibility of biomarker development for drug response similar to this work. 
In addition, I would like to incorporate other important nodes such as PI3K, ERK, MEK, 
JNK in the growth factor receptor networks to further refine our signature genes and 
pathway estimation with better accuracy. Even though the signatures predictions were 
thoroughly validated and tested in breast cancer cell lines, prospective test validation of 





In assessing the feasibility of incorporating gene expression data in EHR, I used 
currently available data elements and standards and followed best practices. In the future, 
I would like to expand our efforts to represent transcriptional data from additional 
platforms such as microarray, NanoStrings and qPCR to show improved generalizability 
across transcriptomics platforms. In addition, I would like to work with expert data 
modelers who have knowledge of genomics data to conduct an extensive validation of 
this model for better reliability and generalizability.  
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